<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">S6NNYpDv96FF8cbWcBGztyC</article-id>
      <article-id pub-id-type="other">00019</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2010001400019</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(10)09500419</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2010001400019</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigo de Revis&#227;o</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Estenose a&#243;rtica grave em pacientes assintom&#225;ticos: o dilema do tratamento cl&#237;nico versus cir&#250;rgico</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Katz</surname>
            <given-names>Marcelo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tarasoutchi</surname>
            <given-names>Fl&#225;vio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Grinberg</surname>
            <given-names>Max</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina </institution>
        <institution content-type="orgdiv2">Hospital das Cl&#237;nicas</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>10</month>
        <year>2010</year>
      </pub-date>
      <volume>95</volume>
      <issue>4</issue>
      <fpage>541</fpage>
      <lpage>546</lpage>
      <history>
        <date date-type="rev-recd">
          <day>02</day>
          <month>02</month>
          <year>2010</year>
        </date>
        <date date-type="received">
          <day>16</day>
          <month>11</month>
          <year>2009</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>02</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>A estenose valvar a&#243;rtica &#233; cada vez mais prevalente concordante com o envelhecimento populacional. Por conseguinte, torna-se mais comum o atendimento de pacientes assintom&#225;ticos com estenose a&#243;rtica grave. Embora os pacientes com estenose a&#243;rtica grave sem sintomas fa&#231;am parte de um mesmo grupo, s&#227;o heterog&#234;neos sob o ponto de vista cl&#237;nico, laboratorial e ecocardiogr&#225;fico. A abordagem desses pacientes traz &#224; tona o dilema do tratamento cl&#237;nico versus cir&#250;rgico: submeter o paciente aos riscos da cirurgia ou mant&#234;-lo em observa&#231;&#227;o cl&#237;nica sob o perigo do dano mioc&#225;rdio irrevers&#237;vel ou mesmo da morte s&#250;bita? Sob esta perspectiva, baseando-se na literatura atual, este artigo fornece ferramentas que auxiliam na estratifica&#231;&#227;o dos pacientes. A &#225;rea valvar, grau de calcifica&#231;&#227;o, velocidade de fluxo transvalvar a&#243;rtico, hipertrofia ventricular esquerda e teste de esfor&#231;o alterado s&#227;o os fatores que colocam os portadores de estenose a&#243;rtica grave assintom&#225;ticos em um grupo denominado de muito alto risco, em que a estrat&#233;gia cir&#250;rgica passa a ser considerada.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Estenose da valva a&#243;rtica</kwd>
        <kwd>disfun&#231;&#227;o ventricular esquerda</kwd>
        <kwd>implante de pr&#243;tese de valva</kwd>
        <kwd>observa&#231;&#227;o cl&#237;nica</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>26</day>
        <month>01</month>
        <year>2011</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>ARTIGO DE REVIS&#195;O</bold>
    </p>
    <p>
      <bold>Estenose a&#243;rtica grave em pacientes assintom&#225;ticos: o dilema do tratamento cl&#237;nico <italic>versus</italic> cir&#250;rgico</bold>
    </p>
    <p>
      <bold>Marcelo Katz; Fl&#225;vio Tarasoutchi; Max Grinberg</bold>
    </p>
    <p>Instituto do Cora&#231;&#227;o do Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo - S&#227;o Paulo, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p>A estenose valvar a&#243;rtica &#233; cada vez mais prevalente concordante com o envelhecimento populacional. Por conseguinte, torna-se mais comum o atendimento de pacientes assintom&#225;ticos com estenose a&#243;rtica grave. Embora os pacientes com estenose a&#243;rtica grave sem sintomas fa&#231;am parte de um mesmo grupo, s&#227;o heterog&#234;neos sob o ponto de vista cl&#237;nico, laboratorial e ecocardiogr&#225;fico. A abordagem desses pacientes traz &#224; tona o dilema do tratamento cl&#237;nico <italic>versus</italic> cir&#250;rgico: submeter o paciente aos riscos da cirurgia ou mant&#234;-lo em observa&#231;&#227;o cl&#237;nica sob o perigo do dano mioc&#225;rdio irrevers&#237;vel ou mesmo da morte s&#250;bita? Sob esta perspectiva, baseando-se na literatura atual, este artigo fornece ferramentas que auxiliam na estratifica&#231;&#227;o dos pacientes. A &#225;rea valvar, grau de calcifica&#231;&#227;o, velocidade de fluxo transvalvar a&#243;rtico, hipertrofia ventricular esquerda e teste de esfor&#231;o alterado s&#227;o os fatores que colocam os portadores de estenose a&#243;rtica grave assintom&#225;ticos em um grupo denominado de muito alto risco, em que a estrat&#233;gia cir&#250;rgica passa a ser considerada.</p>
    <p><bold>Palavras-chave:</bold> Estenose da valva a&#243;rtica, disfun&#231;&#227;o ventricular esquerda/cirurgia, implante de pr&#243;tese de valva, observa&#231;&#227;o cl&#237;nica.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A preval&#234;ncia de estenose a&#243;rtica (EAo) &#233; crescente, particularmente a de etiologia degenerativa, em grande parte relacionada ao envelhecimento populacional. O envelhecimento da popula&#231;&#227;o &#233; um fen&#244;meno mundial, e tamb&#233;m acontece no Brasil. De acordo com estimativas do Instituto Brasileiro de Geografia e Estat&#237;stica (IBGE), no ano de 2050, brasileiros com idade superior aos 75 anos de idade representar&#227;o 10% do total populacional<sup>1</sup>.</p>
    <p>De acordo com Lindroos e cols.<sup>2</sup>, em um estudo ecocardiogr&#225;fico de preval&#234;ncia da EAo, aproximadamente 3% da popula&#231;&#227;o acima de 75 anos de idade apresenta EAo grave de etiologia degenerativa<sup>2</sup>.</p>
    <p>A import&#226;ncia epidemiol&#243;gica da EAo pode ser estimada ao se projetar o cen&#225;rio populacional brasileiro para o ano de 2050. O pa&#237;s ter&#225; 260.000.000 de habitantes, sendo que destes, aproximadamente 10%, ou 26.000.000, ser&#227;o pessoas acima de 75 anos de idade<sup>1</sup>. Considerando o estudo ecocardiogr&#225;fico de Lindroos, teremos 800.000 pessoas acima de 75 anos de idade com EAo grave degenerativa. Somando estes pacientes &#224;queles portadores de EAo das demais faixas et&#225;rias e etiologias, poderemos considerar essa doen&#231;a valvar como uma quest&#227;o de sa&#250;de p&#250;blica, aumentando ainda mais o interesse em seu estudo.</p>
    <p>Al&#233;m do aspecto epidemiol&#243;gico, outra quest&#227;o que se levanta em rela&#231;&#227;o &#224; EAo &#233; a abordagem dos pacientes com EAo grave assintom&#225;ticos. Entende-se que o paciente assintom&#225;tico seja aquele que n&#227;o apresente os sintomas cl&#225;ssicos da EAo: dispneia, angina e s&#237;ncope, independente da faixa et&#225;ria e/ou etiologia. O paciente com EAo grave, sem sintomas, tem sido tema de muito debate entre cl&#237;nicos e cardiologistas nos &#250;ltimos anos. De acordo com o paradigma anterior, baseado em observa&#231;&#245;es da d&#233;cada de 60 e 70, os portadores de EAo grave sem sintomas poderiam ser observados clinicamente, desde que n&#227;o apresentassem disfun&#231;&#227;o ventricular sist&#243;lica, uma vez que a curva de sobrevida desse grupo seria semelhante &#224; da popula&#231;&#227;o em geral<sup>3</sup>.</p>
    <p>Entretanto, o conceito de "benignidade" da EAo grave sem sintomas tem sido refutado nos &#250;ltimos anos, basicamente apoiado em duas premissas:</p>
    <disp-quote>
      <p>1. Nem sempre o paciente assintom&#225;tico est&#225; realmente livre de sintomas, muitas vezes procuram limitar progressivamente suas atividades, mascarando sintomas (principalmente idosos); s&#227;o na realidade "pseudo-assintom&#225;ticos", e, desta forma, tem pior progn&#243;stico.</p>
      <p>2. Os pacientes com estenose a&#243;rtica grave assintom&#225;ticos n&#227;o s&#227;o id&#234;nticos, ou seja, por mais que n&#227;o tenham sintomas e que n&#227;o apresentem disfun&#231;&#227;o ventricular esquerda, existem outras vari&#225;veis que podem aumentar ou diminuir risco destes pacientes, tornando-os, embora parte de um mesmo grupo, heterog&#234;neos.</p>
    </disp-quote>
    <p>O objetivo deste artigo, portanto, &#233; discutir, &#224; luz das evid&#234;ncias atuais, a melhor abordagem do paciente com estenose a&#243;rtica grave assintom&#225;tico, fornecendo ferramentas que auxiliem na decis&#227;o de mant&#234;-lo em observa&#231;&#227;o cl&#237;nica ou submet&#234;-lo ao tratamento cir&#250;rgico.</p>
    <p>
      <bold>Estenose a&#243;rtica: aspectos relevantes</bold>
    </p>
    <p>A EAo &#233; uma doen&#231;a valvar que acomete a valva a&#243;rtica, e que se caracteriza pela obstru&#231;&#227;o &#224; passagem do fluxo sangu&#237;neo da via de sa&#237;da do ventr&#237;culo esquerdo para a aorta. Tem como principais etiologias a doen&#231;a reum&#225;tica, degenerativa, tamb&#233;m denominada ateroscler&#243;tica, e cong&#234;nita<sup>4</sup>.</p>
    <p>Qualquer que seja a causa da EAo, a via final &#233; o processo de calcifica&#231;&#227;o, e redu&#231;&#227;o progressiva do orif&#237;cio valvar. Na evolu&#231;&#227;o da EAo, esta redu&#231;&#227;o progressiva da &#225;rea valvar determina hipertrofia ventricular esquerda (HVE), inicialmente com manuten&#231;&#227;o da fun&#231;&#227;o sist&#243;lica. A HVE permite que o paciente permane&#231;a assintom&#225;tico por um per&#237;odo vari&#225;vel de tempo. Com o passar do tempo ocorre desequil&#237;brio entre os compartimentos muscular, intersticial e vascular, resultando em isquemia e dano mioc&#225;rdico. H&#225; progressiva disfun&#231;&#227;o ventricular, inicialmente diast&#243;lica; na fase final observa-se disfun&#231;&#227;o ventricular sist&#243;lica.</p>
    <p>Na hist&#243;ria natural da EAo, o advento de sintomas (dispneia, angina e s&#237;ncope induzida pelo esfor&#231;o) &#233; um marcador de gravidade, com implica&#231;&#245;es dr&#225;sticas na curva de sobrevida destes pacientes<sup>3,5</sup>.</p>
    <p>O diagn&#243;stico da EAo baseia-se na anamnese, exame f&#237;sico, e avalia&#231;&#227;o complementar. A anamnese deve ser criteriosa objetivando-se estabelecer a real capacidade funcional do paciente e identificar a presen&#231;a de sintomas relacionados &#224; estenose a&#243;rtica. &#201; muito comum pacientes limitarem suas atividades com o advento dos sintomas<sup>6</sup>.</p>
    <p>Na avalia&#231;&#227;o complementar, destaca-se o papel da ecocardiografia com Doppler (ECO)<sup>7,8</sup>. O ECO permite a confirma&#231;&#227;o diagn&#243;stica e a estratifica&#231;&#227;o de gravidade da EAo, que pode ser leve, moderada ou grave. De acordo com a <italic>American Heart Association<sup>7</sup>,</italic> a EAo grave pode ser definida como aquela com &#225;rea valvar menor que 1,0 cm<sup>2</sup>, gradiente m&#233;dio transvalvar a&#243;rtico maior ou igual a 40 mmHg, e/ou velocidade de jato transvalvar a&#243;rtico no pico da s&#237;stole maior que 4 m/s. Uma subclassifica&#231;&#227;o da EAo em EAo muito grave tem sido sugerida<sup>9,10</sup>. Seria aquela com &#225;rea valvar a&#243;rtica menor ou igual a 0,7 cm<sup>2</sup> e/ou &#225;rea valvar indexada menor ou igual a 0,4 cm<sup>2</sup>/m<sup>2</sup>.</p>
    <p>O tratamento definitivo da EAo grave, quando indicado, &#233; cir&#250;rgico, sendo que a o tratamento padr&#227;o, at&#233; o presente momento, &#233; a troca da valva a&#243;rtica por uma pr&#243;tese, que pode ser biol&#243;gica ou met&#225;lica. As principais indica&#231;&#245;es para o tratamento cir&#250;rgico s&#227;o<sup>7,8</sup>:</p>
    <disp-quote>
      <p>&#149; EAo grave em pacientes sintom&#225;ticos (dispneia, angina e s&#237;ncope)</p>
      <p>&#149; EAo grave em pacientes que ser&#227;o submetidos &#224; cirurgia de revasculariza&#231;&#227;o mioc&#225;rdica</p>
      <p>&#149; EAo grave em pacientes que ser&#227;o submetidos &#224; cirurgia em aorta ou outras valvas</p>
      <p>&#149; EAo grave em pacientes com disfun&#231;&#227;o sist&#243;lica ventricular</p>
    </disp-quote>
    <p>Mais recentemente, tem sido utilizada &#224; t&#233;cnica de implante percut&#226;neo da valva a&#243;rtica<sup>11,12</sup>. Trata-se de procedimento realizado por via arterial femoral, com coloca&#231;&#227;o de pr&#243;tese biol&#243;gica a&#243;rtica ancorada em uma estrutura aramada que lembra um "grande <italic>stent</italic>", realizada em centros com experi&#234;ncia neste procedimento, sendo que ainda n&#227;o substitui o procedimento cir&#250;rgico convencional; reservada a casos selecionados em que h&#225; alto risco cir&#250;rgico.</p>
    <p>
      <bold>Estenose a&#243;rtica grave em pacientes assintom&#225;ticos: o grande dilema</bold>
    </p>
    <p>A abordagem dos pacientes com EAo grave distingue inicialmente 3 grupos:</p>
    <disp-quote>
      <p>&#149; Pacientes com EAo grave sintom&#225;ticos e/ou com disfun&#231;&#227;o sist&#243;lica do ventr&#237;culo esquerdo. Estes pacientes t&#234;m indica&#231;&#227;o formal ao tratamento cir&#250;rgico, e desde que n&#227;o haja fatores/comorbidades que contra-indiquem a cirurgia, esta deve ser considerada como tratamento de escolha.</p>
      <p>&#149; Pacientes com EAo grave sintom&#225;ticos e/ou com disfun&#231;&#227;o sist&#243;lica do ventr&#237;culo esquerdo, mas com comorbidades que contra-indiquem tratamento cir&#250;rgico, ou ainda que recusem cirurgia. Nestes casos o tratamento ser&#225; paliativo, embora haja perspectiva futura da possibilidade alternativa de tratamento com implante percut&#226;neo de pr&#243;tese valvar a&#243;rtica<sup>11,12</sup>.</p>
      <p>&#149; Finalmente, o terceiro grupo, composto por pacientes com EAo grave, assintom&#225;ticos, com fun&#231;&#227;o ventricular preservada, objeto maior deste artigo. Como destacamos, embora fa&#231;am parte do mesmo grupo, s&#227;o heterog&#234;neos. A conduta, portanto ser&#225; individualizada.</p>
    </disp-quote>
    <p>A decis&#227;o terap&#234;utica para o paciente com EAo grave, assintom&#225;tico, traz &#224; tona o dilema: mant&#234;-lo em observa&#231;&#227;o cl&#237;nica, ou oper&#225;-lo profilaticamente.</p>
    <p>A estrat&#233;gia de operar profilaticamente todos os pacientes com EAo grave assintom&#225;ticos n&#227;o &#233; vi&#225;vel. Imaginando que a "cirurgia profil&#225;tica" fosse a rotina, estar&#237;amos expondo 100% dos pacientes com EAo grave assintom&#225;ticos a um risco de 3% a 4% relacionado ao procedimento cir&#250;rgico, somado a um risco de 1% ao ano relacionado &#224; presen&#231;a de pr&#243;tese valvar, beneficiando aproximadamente 1% desta popula&#231;&#227;o que teria o risco de morte s&#250;bita por ano<sup>5,13-15</sup>.</p>
    <p>Por outro lado, manter todos os pacientes desse grupo em observa&#231;&#227;o cl&#237;nica pode n&#227;o ser seguro. Na realidade, estudos observacionais mais recentes relacionados &#224; hist&#243;ria natural da EAo grave em assintom&#225;ticos, mostram que este grupo n&#227;o &#233; t&#227;o "benigno" como se imaginava em d&#233;cadas anteriores<sup>16-21</sup>.</p>
    <p>Em 1997, Otto e cols.<sup>18</sup> apresentam um estudo em que 123 pacientes com EAo grave assintom&#225;ticos foram acompanhados prospectivamente por 2,5 &#177; 1,4 anos. Nesse estudo a probabilidade de sobrevida livre de sintomas para os pacientes assintom&#225;ticos foi de 93% no primeiro ano, 62% no terceiro ano e 26% no quinto ano. Atrav&#233;s de an&#225;lise multivariada, a velocidade de jato transvalvar a&#243;rtico, o aumento da velocidade de jato transvalvar a&#243;rtico e a mudan&#231;a do <italic>status</italic> funcional foram preditores independentes de &#243;bito ou necessidade de cirurgia. A probabilidade do paciente permanecer vivo, sem necessidade de cirurgia aos 2 anos de seguimento, foi de apenas 21% para os que apresentavam na inclus&#227;o do estudo velocidade de jato transvalvar a&#243;rtico maior que 4 m/s.</p>
    <p>Em 2000, Rosenhek e cols.<sup>21</sup> publicam o resultado de um estudo prospectivo em que 126 pacientes portadores de EAo grave assintom&#225;ticos foram seguidos por 22 &#177; 18 meses. Ao final do acompanhamento, a probabilidade de sobrevida calculada para os pacientes assintom&#225;ticos foi de 93% no primeiro ano, 91% no segundo ano e 87% no quarto ano. Atrav&#233;s de an&#225;lise multivariada, o grau de calcifica&#231;&#227;o valvar foi preditor independente de eventos combinados que inclu&#237;ram desenvolvimento de sintomas e/ou &#243;bito. A probabilidade de sobrevida livre de sintomas para os pacientes assintom&#225;ticos que apresentavam calcifica&#231;&#227;o valvar a&#243;rtica moderada ou intensa foi de 60% no primeiro ano, 47% no segundo ano e apenas 20% no quarto ano.</p>
    <p>Em 2001, Amato e cols.<sup>16</sup> apresentam o resultado de um estudo prospectivo que acompanhou 66 pacientes com EAo grave assintom&#225;ticos. Todos os pacientes foram submetidos a teste de esfor&#231;o em esteira, com o objetivo de estratific&#225;-los. Houve quatro casos de morte s&#250;bita durante o acompanhamento, sendo que nestes, o teste de esfor&#231;o havia sido positivo e a &#225;rea valvar a&#243;rtica era menor ou igual a 0,6 cm<sup>2</sup>.</p>
    <p>Em 2004, Bergler-Klein e cols.<sup>22</sup> estudaram o BNP e o NT-proBNP como marcadores progn&#243;sticos em pacientes com estenose a&#243;rtica. O foco era na an&#225;lise da sobrevida livre de sintomas em assintom&#225;ticos. O valor de BNP menor que 130 pg/ml e de NT-proBNP menor que 80 pmol/l (678 pg/ml) foram preditores de sobrevida livre de sintomas por um per&#237;odo de 6 a 9 meses<sup>22</sup>.</p>
    <p>Em 2005, o grupo de Pellikka e cols.<sup>20</sup> apresenta o resultado de um grande estudo em que 622 pacientes assintom&#225;ticos com EAo grave foram acompanhados prospectivamente por 5 anos. Nesse estudo, a probabilidade de pacientes n&#227;o operados permanecerem livres de sintomas foi de apenas 33% em 5 anos, enquanto que a probabilidade de sobrevida sem cirurgia foi de 25% em 5 anos. O risco de morte s&#250;bita, n&#227;o precedida por sintomas, foi de aproximadamente 1% ao ano. Nesse trabalho, a partir de 2 anos de seguimento, o paciente assintom&#225;tico passou a ter progn&#243;stico pior do que a da popula&#231;&#227;o em geral, mesmo sem apresentar sintomas. Idade, insufici&#234;ncia renal cr&#244;nica e velocidade de jato transvalvar a&#243;rtico foram preditores de mortalidade<sup>20</sup>.</p>
    <p>Mais recentemente, o grupo do Dr. Jean-Luc Monin e cols.<sup>17</sup> conduziu um estudo que envolveu 107 pacientes com EAo grave assintom&#225;ticos. O objetivo era desenvolver um escore de risco que pudesse ser aplicado, e que fosse capaz de predizer a chance destes pacientes apresentarem eventos adversos ao longo do tempo. Os pacientes foram seguidos por 24 meses e &#243;bito ou necessidade de cirurgia foram computados como evento adverso. Os preditores independentes de eventos adversos encontrados neste estudo foram utilizados para a constru&#231;&#227;o do escore, que em seguida foi aplicado em uma segunda popula&#231;&#227;o de 107 pacientes com EAo grave, assintom&#225;ticos, com o intuito de validar o escore. As vari&#225;veis preditoras de desfecho foram sexo feminino, velocidade de jato transvalvar a&#243;rtico no pico da s&#237;stole, e o valor inicial do BNP. Uma formula foi constru&#237;da para c&#225;lculo do escore:</p>
    <p>
      <graphic xlink:href="1678-4170-abc-95-04-0541-00019-e01.jpg"/></p>
    <p>Os valores obtidos para o escore foram agrupados em quartis: Q1 12,9; Q2 14,6; Q3 16,2 e Q4 19,7. A probabilidade de sobrevida livre de eventos em 20 meses foi de 80% nos pacientes do primeiro quartil e apenas 7% entre os pacientes do &#250;ltimo quartil. Embora com resultados robustos, a aplica&#231;&#227;o sistem&#225;tica de escore de risco, proposta pelo grupo do Dr. Monin<sup>17</sup>, necessita de valida&#231;&#227;o para tornar-se rotina<sup>23</sup>.</p>
    <p>Se por um lado, os estudos prospectivos que avaliaram pacientes com EAo grave, assintom&#225;ticos, mostram que o risco de morte s&#250;bita nesses pacientes &#233; em torno de 1% ao ano, tamb&#233;m revelam que o grupo &#233; realmente heterog&#234;neo, e que par&#226;metros cl&#237;nicos, laboratoriais e ecocardiogr&#225;ficos determinam maior ou menor risco para estes pacientes.</p>
    <p>O paciente assintom&#225;tico al&#233;m de ter o risco de morte s&#250;bita, tem tamb&#233;m o risco de dano irrevers&#237;vel ao mioc&#225;rdio em casos em que a cirurgia &#233; postergada<sup>23</sup>. Esses riscos devem ser levados em conta quando da escolha da estrat&#233;gia conservadora ou cir&#250;rgica.</p>
    <p>O que se tem buscado, portanto, &#233; a estratifica&#231;&#227;o mais refinada desse grupo de pacientes, com o objetivo de identificar, dentre os pacientes com EAo grave assintom&#225;ticos, aqueles de maior risco, e que, portanto, se beneficiam da cirurgia. O objetivo &#233; evitar justamente a morte s&#250;bita e/ou o dano irrevers&#237;vel ao mioc&#225;rdio. Neste prop&#243;sito, e baseado em diretrizes e estudos observacionais mais recentes, os principais fatores de risco seriam<sup>7,8,10</sup>:</p>
    <disp-quote>
      <p>&#149; EAo muito grave (&#225;rea valvar <underline>&lt;</underline> 0,7 cm<sup>2</sup> ou &#225;rea valvar indexada <underline>&lt;</underline> 0,4 cm<sup>2</sup>/m<sup>2</sup></p>
      <p>&#149; Incremento acelerado de gravidade da EAo (definido como aumento na velocidade de jato transvalvar a&#243;rtico maior que 0,30 m/s ao ano)</p>
      <p>&#149; Calcifica&#231;&#227;o valvar a&#243;rtica</p>
      <p>&#149; Presen&#231;a de isquemia documentada/ doen&#231;a arterial coronariana</p>
      <p>&#149; Disfun&#231;&#227;o sist&#243;lica ventricular (quando presente indica cirurgia)</p>
      <p>&#149; Dilata&#231;&#227;o ventricular esquerda com perda de fun&#231;&#227;o sist&#243;lica ("<italic>afterload mismatch</italic>")</p>
      <p>&#149; Hipertrofia ventricular esquerda excessiva ou rapidamente progressiva (12 a 14 mm em mulheres e 14 a 16 mm em homens)</p>
      <p>&#149; Idade (acima de 60 anos de idade)</p>
      <p>&#149; Outras comorbidade n&#227;o card&#237;acas</p>
    </disp-quote>
    <p>
      <bold>A resposta para o dilema: conduta individualizada</bold>
    </p>
    <p>Como exposto, embora pacientes com EAo grave assintom&#225;ticos fa&#231;am parte de um mesmo grupo, na realidade s&#227;o heterog&#234;neos sob o ponto de vista cl&#237;nico, laboratorial e ecocardiogr&#225;fico. Como consequ&#234;ncia, tamb&#233;m o progn&#243;stico torna-se dependente destas particularidades. Portanto, a conduta para estes pacientes deve ser individualizada. Em um extremo, para os pacientes de baixo risco, a conduta &#233; conservadora, expectante. No outro extremo, para os pacientes de alto risco, a conduta &#233; cir&#250;rgica, com troca valvar a&#243;rtica.</p>
    <p>Individualizar risco em pacientes assintom&#225;ticos tamb&#233;m &#233; a sugest&#227;o das principais diretrizes. De acordo com o consenso europeu, pacientes com EAo grave assintom&#225;ticos, com fun&#231;&#227;o ventricular preservada, que apresentem calcifica&#231;&#227;o valvar exuberante, r&#225;pido aumento da velocidade de jato transvalvar a&#243;rtico, ou ainda teste de esfor&#231;o alterado seriam candidatos &#224; cirurgia, assim como aqueles que ser&#227;o submetidos a outra cirurgia card&#237;aca concomitante, por exemplo revasculariza&#231;&#227;o mioc&#225;rdica associada<sup>8</sup>. O consenso americano indica cirurgia para os pacientes que apesar de assintom&#225;ticos, apresentem calcifica&#231;&#227;o valvar exuberante ou r&#225;pido aumento da velocidade de jato transvalvar a&#243;rtico<sup>7</sup>. A experi&#234;ncia nacional destaca a import&#226;ncia do teste de esfor&#231;o na estratifica&#231;&#227;o destes pacientes<sup>16</sup>.</p>
    <p>Baseados no que foi exposto, propomos a seguinte abordagem para o paciente assintom&#225;tico com EAo grave:</p>
    <p>
      <bold>1. Confirma&#231;&#227;o do diagn&#243;stico de EAo grave</bold>
    </p>
    <p>O exame f&#237;sico, complementado pela ecocardiografia permite a confirma&#231;&#227;o da EAo e a avalia&#231;&#227;o de sua gravidade. De acordo com os par&#226;metro ecocardiogr&#225;ficos, EAo grave pode ser definida como aquela que apresenta gradiente m&#233;dio de press&#227;o transvalvar a&#243;rtico maior que 40 mmHg, &#225;rea valvar a&#243;rtica menor que 1 cm<sup>2</sup> e/ou velocidade de jato transvalvar a&#243;rtico no pico da s&#237;stole maior que 4m/s. Sugere-se que EAo muito grave seja aquela em que a &#225;rea valvar &#233; menor que 0,7 cm<sup>2</sup> ou a &#225;rea valvar indexada &#233; menor que 0,4 cm<sup>2</sup>. Quando houver d&#250;vidas acerca da gravidade da EAo, uma boa alternativa &#233; a avalia&#231;&#227;o hemodin&#226;mica, com realiza&#231;&#227;o de manometria e detec&#231;&#227;o de gradiente de press&#227;o transvalvar a&#243;rtico.</p>
    <p>
      <bold>2. Elucida&#231;&#227;o do real <italic>status</italic> funcional. Ser&#225; que o paciente &#233; realmente assintom&#225;tico ou esta autolimitado?</bold>
    </p>
    <p>A anamnese destes pacientes deve ser detalhada e exaustiva, focada nas atividades cotidianas dos pacientes. &#201; muito comum um paciente que caminhava sem problemas, agora, mais limitado, restringir-se nas tarefas dom&#233;sticas, e mesmo assim dizer que se sente bem, quando na verdade deixou de executar o n&#237;vel de esfor&#231;o de outrora.</p>
    <p>Uma boa alternativa complementar, na tentativa de elucidar a quest&#227;o do <italic>status</italic> funcional, seria submeter esses pacientes a uma avalia&#231;&#227;o funcional, como por exemplo, o teste ergom&#233;trico<sup>24</sup>. O teste pode fornecer dados importantes e selecionar pacientes ditos pseudoassintom&#225;ticos. O teste tamb&#233;m auxilia nos casos de s&#237;ncope isolada (sem angina ou dispneia). A s&#237;ncope isolada, como &#250;nica manifesta&#231;&#227;o cl&#237;nica da EAo, &#233; pouco comum<sup>25,26</sup>. Nesses casos, a presen&#231;a de s&#237;ncope durante o teste define a associa&#231;&#227;o sintoma-esfor&#231;o, indicando a cirurgia. Ressalte-se, ainda, que o teste de esfor&#231;o pode inclusive ser associado &#224; ecocardiografia<sup>27</sup>. A ecocardiografia de esfor&#231;o &#233; outro m&#233;todo de estratifica&#231;&#227;o funcional destes pacientes.</p>
    <p>Embora o teste de esfor&#231;o seja pouco realizado na pr&#225;tica cl&#237;nica<sup>28</sup>, em metan&#225;lise recente<sup>29</sup>, que analisou o papel do teste ergom&#233;trico na avalia&#231;&#227;o de pacientes com EAo grave assintom&#225;ticos, os autores destacam que o teste &#233; seguro e eficaz em identificar pacientes com alto risco para eventos card&#237;acos adversos e morte s&#250;bita. O teste pode ser utilizado para estratifica&#231;&#227;o de risco e para defini&#231;&#227;o do melhor momento de operar os pacientes.</p>
    <p>O teste de esfor&#231;o ganha cada vez mais espa&#231;o, e enquanto sua recomenda&#231;&#227;o &#233; classe IIb no consenso americano de valvopatias<sup>7</sup> de 2006, a sociedade europeia de cardiologia em 2007 o coloca como ben&#233;fico e efetivo, incluindo o teste no algoritmo de tomada de decis&#227;o para os pacientes com EAo grave assintom&#225;ticos<sup>8</sup>.</p>
    <p>
      <bold>3. Avalia&#231;&#227;o da fun&#231;&#227;o ventricular esquerda</bold>
    </p>
    <p>A ecocardiografia permite a avalia&#231;&#227;o da fun&#231;&#227;o ventricular sist&#243;lica<sup>30</sup>. Nos pacientes com EAo grave, mesmo que assintom&#225;ticos, se houver disfun&#231;&#227;o ventricular sist&#243;lica, o tratamento cir&#250;rgico deve ser considerado.</p>
    <p>
      <bold>4. Defini&#231;&#227;o de conduta cl&#237;nica ou cir&#250;rgica para os pacientes com EAo grave, assintom&#225;ticos, com fun&#231;&#227;o ventricular preservada</bold>
    </p>
    <p>Nestes pacientes, a conduta deve ser individualizada<sup>10,31</sup>. Alguns par&#226;metros podem colocar o paciente em muito alto risco, e entre os fatores apresentados anteriormente, aqueles que definem muito alto risco s&#227;o:</p>
    <disp-quote>
      <p>&#149; Teste de esfor&#231;o positivo (com sintomas evidentes ou hipotens&#227;o ao esfor&#231;o).</p>
      <p>&#149; &#193;rea valvar a&#243;rtica menor ou igual a 0,7 cm<sup>2</sup> ou &#225;rea valvar indexada menor ou igual a 0,4 cm<sup>2</sup>/m<sup>2</sup>. A indexa&#231;&#227;o da &#225;rea pela superf&#237;cie corp&#243;rea &#233; importante pelas diferen&#231;as antropom&#233;tricas nos diversos pacientes.</p>
      <p>&#149; Velocidade de jato transvalvar a&#243;rtico rapidamente progressiva, com taxa de aumento anual maior que 0,30 m/s ao ano.</p>
      <p>&#149; Calcifica&#231;&#227;o valvar a&#243;rtica moderada a intensa se associada com r&#225;pido aumento da velocidade de fluxo transvalvar a&#243;rtico.</p>
      <p>&#149; Hipertrofia ventricular excessiva, outro marcador de gravidade, especialmente se somada &#224; &#225;rea valvar reduzida. A hipertrofia ventricular por um lado permite a manuten&#231;&#227;o do d&#233;bito card&#237;aco frente &#224; sobrecarga press&#243;rica imposta pela EAo. Por outro lado, altera a fun&#231;&#227;o diast&#243;lica, diminui perfus&#227;o coronariana e est&#225; relacionada com aumento de mortalidade<sup>32</sup>.</p>
    </disp-quote>
    <p>Sugerimos, baseados na literatura atual, que pacientes assintom&#225;ticos com estenose a&#243;rtica grave, que apresentem os fatores de muito alto risco sejam candidatos ao tratamento cir&#250;rgico. O risco cir&#250;rgico &#233; relativamente baixo comparado ao risco de r&#225;pido desenvolvimento de sintomas e morte s&#250;bita espec&#237;fico para esse grupo de muito alto risco. Embora ainda n&#227;o haja estudo randomizado que aborde conduta cl&#237;nica <italic>versus</italic> cir&#250;rgica nesses pacientes, &#233; cada vez mais aceita a estrat&#233;gia de n&#227;o retardar o tratamento cir&#250;rgico, isto porque o dano mioc&#225;rdio pode ser irrevers&#237;vel, os sintomas podem se desenvolver rapidamente sem a correta percep&#231;&#227;o do paciente, e o risco de morte s&#250;bita eleva-se drasticamente.</p>
    <p>Uma considera&#231;&#227;o especial deve ser dada &#224; popula&#231;&#227;o de idosos. Quando analisamos consensos e diretrizes, n&#227;o h&#225; refer&#234;ncia &#224; idade-limite que contraindique o tratamento cir&#250;rgico. Na realidade, o que os estudos revelam atrav&#233;s de s&#233;ries de casos, &#233; que mesmo no idoso, o tratamento cir&#250;rgico, quando indicado, &#233; melhor do que conduta expectante<sup>33</sup>. Em se tratando do paciente idoso, deveremos buscar os fatores de muito alto risco, mas sempre levando em considera&#231;&#227;o a equa&#231;&#227;o: expectativa de vida x qualidade de vida x risco do tratamento cir&#250;rgico, para que a melhor decis&#227;o terap&#234;utica seja tomada.</p>
    <p>
      <bold>Exemplos de situa&#231;&#245;es cl&#237;nicas</bold>
    </p>
    <p>Exemplificaremos o que foi discutido neste artigo atrav&#233;s de tr&#234;s situa&#231;&#245;es cl&#237;nicas:</p>
    <p>
      <bold>Situa&#231;&#227;o 1</bold>
    </p>
    <p>Homem de 53 anos, executivo, hipertenso e dislipid&#234;mico, assintom&#225;tico no dia-a-dia, joga futebol de campo com os amigos 2 vezes por semana. Em consulta com o cardiologista, detectado sopro sugestivo de EAo. Ecocardiograma revela: c&#226;maras card&#237;acas com dimens&#245;es normais, espessura do septo e da parede posterior de 11 mm, fun&#231;&#227;o biventricular normal, valva a&#243;rtica calcificada, com estenose a&#243;rtica grave, gradiente m&#233;dio de press&#227;o transvalvar a&#243;rtico de 45 mmHg, velocidade de jato transvalvar a&#243;rtico de 4,1 m/s, &#225;rea valvar a&#243;rtica de 1 cm<sup>2</sup>. Demais valvas sem altera&#231;&#245;es. BNP de 70 pg/ml. O cardiologista orienta evitar o futebol, indica um teste de esfor&#231;o, que &#233; normal, e repete o ecocardiograma em 6 meses, cujo resultado &#233; id&#234;ntico ao exame inicial. A conduta indicada &#233; expectante, conservadora. Indicado retornos semestrais ou mais precoces se aparecimento de sintomas.</p>
    <p>
      <bold>Situa&#231;&#227;o 2</bold>
    </p>
    <p>Homem de 75 anos, aposentado, assintom&#225;tico no dia-a-dia, caminha regularmente. Em consulta com o cardiologista &#233; detectado sopro sugestivo de EAo. O ecocardiograma revela: c&#226;maras card&#237;acas de dimens&#245;es normais, espessura do septo e da parede posterior de 12mm, fun&#231;&#227;o biventricular normal, valva a&#243;rtica calcificada, com estenose a&#243;rtica grave, gradiente m&#233;dio de press&#227;o transvalvar a&#243;rtico de 45 mmHg, velocidade de jato transvalvar a&#243;rtico de 4,2 m/s, &#225;rea valvar a&#243;rtica de 0,9 cm<sup>2</sup>. Demais valvas sem altera&#231;&#245;es. BNP de 100 pg/ml. O cardiologista indica um teste de esfor&#231;o, que &#233; normal. A conduta inicial &#233; expectante, com retorno em 6 meses. No retorno (6 meses) o paciente permanece assintom&#225;tico, e novo ecocardiograma revela espessura do septo e da parede posterior de 14 mm, fun&#231;&#227;o biventricular normal, valva a&#243;rtica calcificada, com estenose a&#243;rtica grave, gradiente m&#233;dio de press&#227;o transalvar a&#243;rtico de 58 mmHg, velocidade de jato transvalvar a&#243;rtico de 4,9 m/s, &#225;rea valvar a&#243;rtica de 0,7 cm<sup>2</sup>. Observa-se r&#225;pida evolu&#231;&#227;o da EAo em 6 meses (aumento da espessura de septo e parede, diminui&#231;&#227;o de &#225;rea valvar, aumento de gradiente e velocidade de jato). O paciente &#233; classificado como de muito alto risco pela r&#225;pida evolu&#231;&#227;o da estenose a&#243;rtica e conduta indicada &#233; cir&#250;rgica.</p>
    <p>
      <bold>Situa&#231;&#227;o 3</bold>
    </p>
    <p>Mulher de 62 anos, sem doen&#231;as diagnosticadas, assintom&#225;tica no dia-a-dia, aposentada. A filha notou que a m&#227;e tem sa&#237;do menos &#224; rua, e suas atividades s&#227;o cada vez mais dom&#233;sticas. O cardiologista detectou sopro sugestivo de EAo. Ecocardiograma revela: c&#226;maras card&#237;acas com dimens&#245;es normais, espessura do septo e da parede posterior de 13mm, fun&#231;&#227;o biventricular normal, valva a&#243;rtica calcificada, com estenose a&#243;rtica grave, gradiente m&#233;dio de press&#227;o transvalvar a&#243;rtico de 58 mmHg, velocidade de jato transvalvar a&#243;rtico de 4,8 m/s e &#225;rea valvar de 0,8 cm<sup>2</sup>. Demais valvas sem altera&#231;&#245;es. BNP de 200 pg/ml. O cardiologista indica um teste de esfor&#231;o para avalia&#231;&#227;o do real status funcional da paciente: no segundo minuto do teste a paciente apresenta hipotens&#227;o com sensa&#231;&#227;o de pr&#233;-sincope, e o teste &#233; interrompido, com recupera&#231;&#227;o total da paciente. O cardiologista interpreta o caso como de muito alto risco, julga que provavelmente a paciente se autolimitava, e indica a cirurgia de troca valvar a&#243;rtica.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>Os pacientes com EAo grave assintom&#225;ticos fazem parte de um grupo heterog&#234;neo do ponto de vista cl&#237;nico, laboratorial e ecocardiogr&#225;fico. Destaca-se dentro deste grupo, uma parcela de pacientes classificados como de muito alto risco. Os crit&#233;rios de muito alto risco s&#227;o: teste de esfor&#231;o alterado, &#225;rea valvar a&#243;rtica menor ou igual a 0,7 cm<sup>2</sup> ou &#225;rea valvar indexada menor ou igual a 0,4 cm<sup>2</sup>/m<sup>2</sup>, velocidade de jato transvalvar a&#243;rtico rapidamente progressiva, calcifica&#231;&#227;o valvar a&#243;rtica moderada a intensa, hipertrofia ventricular excessiva. Para os pacientes de muito alto risco a estrat&#233;gia cir&#250;rgica deve ser considerada frente &#224; conduta conservadora.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <bold>Refer&#234;ncias</bold>
    </p>
    <p>1. Instituto Brasileiro de Geografia e Estat&#237;stica (IBGE).2008. [Acesso em 2009 out 15]. Dispon&#237;vel em <ext-link ext-link-type="uri" xlink:href="http://www.ibge.gov.br/home/estatistica/populacao/projecao_da_populacao/piramide/piramide.shtm"><p content-type="break">http://www.ibge.gov.br/home/estatistica/populacao/projecao_da_populacao/piramide </p><p content-type="break"> /piramide.shtm</p></ext-link></p>
    <p>
      <fn id="back" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Marcelo Katz </p>
        <p> Rua Jo&#227;o Moura, 690/92 </p>
        <p> Pinheiros - 05412-001 </p>
        <p> S&#227;o Paulo, SP - Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="mksp1975@gmail.com">mksp1975@gmail.com</email>
        </p>
        <p>
          <email xlink:href="mkatz@terra.com.br">mkatz@terra.com.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 16/11/09; revisado recebido em 02/02/10; aceito em 24/02/10.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>2. Lindroos M,    Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in    the elderly: an echocardiographic study of a random population sample. J Am    Coll Cardiol. 1993; 21 (5): 1220-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>1220</fpage>
          <lpage>5</lpage>
          <issue>5</issue>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lindroos</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kupari</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Heikkila</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tilvis</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>3. Ross J Jr, Braunwald    E. Aortic stenosis. Circulation. 1968; 38 (1 Suppl): 61-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Aortic stenosis</article-title>
          <source>Circulation</source>
          <date>
            <year>1968</year>
          </date>
          <fpage>61</fpage>
          <lpage>7</lpage>
          <volume>38</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ross J</surname>
              <given-names>Jr</given-names>
            </name>
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>4. Passik CS, Ackermann    DM, Pluth JR, Edwards WD. Temporal changes in the causes of aortic stenosis:    a surgical pathologic study of 646 cases. Mayo Clin Proc. 1987; 62 (2): 119-23.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Temporal changes in the causes of aortic stenosis: a surgical pathologic study of 646 cases</article-title>
          <source>Mayo Clin Proc</source>
          <date>
            <year>1987</year>
          </date>
          <fpage>119</fpage>
          <lpage>23</lpage>
          <issue>2</issue>
          <volume>62</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Passik</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Ackermann</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Pluth</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>WD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>5. Carabello BA.    Evaluation and management of patients with aortic stenosis. Circulation. 2002;    105 (15): 1746-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Evaluation and management of patients with aortic stenosis</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1746</fpage>
          <lpage>50</lpage>
          <issue>15</issue>
          <volume>105</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Carabello</surname>
              <given-names>BA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>6. Cheitlin MD.    Asymptomatic adult patients with aortic stenosis: should they ever have aortic    valve replacement? Am Heart Hosp J. 2005; 3 (4): 243-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Asymptomatic adult patients with aortic stenosis: should they ever have aortic valve replacement?</article-title>
          <source>Am Heart Hosp J</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>243</fpage>
          <lpage>6</lpage>
          <issue>4</issue>
          <volume>3</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cheitlin</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>7. Bonow RO, Carabello    BA, Kanu C, de Leon AC Jr, Faxon DP, Freed MD, et al. ACC/AHA 2006 guidelines    for the management of patients with valvular heart disease: a report of the    American College of Cardiology/American Heart Association Task Force on Practice    Guidelines (writing committee to revise the 1998 Guidelines for the Management    of Patients With Valvular Heart Disease): developed in collaboration with the    Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular    Angiography and Interventions and the Society of Thoracic Surgeons. Circulation.    2006; 114 (5):e84-231.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons</article-title>
          <source>Circulation</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>e84</fpage>
          <lpage>231</lpage>
          <issue>5</issue>
          <volume>114</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bonow</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Carabello</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Kanu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>de Leon AC</surname>
              <given-names>Jr</given-names>
            </name>
            <name>
              <surname>Faxon</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Freed</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>8. Vahanian A,    Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, et al. Guidelines on    the management of valvular heart disease: the Task Force on the Management of    Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007;    28 (2): 230-68.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Guidelines on the management of valvular heart disease: the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>230</fpage>
          <lpage>68</lpage>
          <issue>2</issue>
          <volume>28</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Vahanian</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Baumgartner</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bax</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Butchart</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dion</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Filippatos</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>9. Rahimtoola SH.    Perspective on valvular heart disease: an update. J Am Coll Cardiol. 1989; 14    (1): 1-23.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Perspective on valvular heart disease: an update</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1989</year>
          </date>
          <fpage>1</fpage>
          <lpage>23</lpage>
          <issue>1</issue>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rahimtoola</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>10. Rahimtoola    SH. Valvular heart disease: a perspective on the asymptomatic patient with severe    valvular aortic stenosis. Eur Heart J. 2008; 29 (14): 1783-90.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Valvular heart disease: a perspective on the asymptomatic patient with severe valvular aortic stenosis</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1783</fpage>
          <lpage>90</lpage>
          <issue>14</issue>
          <volume>29</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rahimtoola</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>11. Vahanian A,    Alfieri O, Al-Attar N, Antunes M, Bax J, Cormier B, et al. Transcatheter valve    implantation for patients with aortic stenosis: a position statement from the    European Association of Cardio-Thoracic Surgery (EACTS) and the European Society    of Cardiology (ESC), in collaboration with the European Association of Percutaneous    Cardiovascular Interventions (EAPCI). Eur Heart J. 2008; 29 (11): 1463-70.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI)</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1463</fpage>
          <lpage>70</lpage>
          <issue>11</issue>
          <volume>29</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Vahanian</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Alfieri</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Al-Attar</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Antunes</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bax</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cormier</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>12. Perin MA, Brito    FS Jr, Almeida BO, Pereira MA, Abizaid A, Tarasoutchi F, et al. Percutaneous    aortic valve replacement for the treatment of aortic stenosis: early experience    in Brazil. Arq Bras Cardiol. 2009; 93 (3): 299-306.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Percutaneous aortic valve replacement for the treatment of aortic stenosis: early experience in Brazil</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>299</fpage>
          <lpage>306</lpage>
          <issue>3</issue>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Perin</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Brito FS</surname>
              <given-names>Jr</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>BO</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Abizaid</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tarasoutchi</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>13. Carabello BA.    Timing of valve replacement in aortic stenosis: moving closer to perfection.    Circulation. 1997; 95 (9): 2241-3.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Timing of valve replacement in aortic stenosis: moving closer to perfection</article-title>
          <source>Circulation</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>2241</fpage>
          <lpage>3</lpage>
          <issue>9</issue>
          <volume>95</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Carabello</surname>
              <given-names>BA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>14. Carabello BA.    Clinical practice: aortic stenosis. N Engl J Med. 2002; 346 (9): 677-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical practice: aortic stenosis</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>677</fpage>
          <lpage>82</lpage>
          <issue>9</issue>
          <volume>346</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Carabello</surname>
              <given-names>BA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>15. Hammermeister    K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years    after valve replacement with a mechanical versus a bioprosthetic valve: final    report of the Veterans Affairs randomized trial. J Am Coll Cardiol. 2000; 36    (4): 1152-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1152</fpage>
          <lpage>8</lpage>
          <issue>4</issue>
          <volume>36</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hammermeister</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sethi</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Henderson</surname>
              <given-names>WG</given-names>
            </name>
            <name>
              <surname>Grover</surname>
              <given-names>FL</given-names>
            </name>
            <name>
              <surname>Oprian</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rahimtoola</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>16. Amato MC, Moffa    PJ, Werner KE, Ramires JA. Treatment decision in asymptomatic aortic valve stenosis:    role of exercise testing. Heart. 2001; 86 (4): 381-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Treatment decision in asymptomatic aortic valve stenosis: role of exercise testing</article-title>
          <source>Heart</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>381</fpage>
          <lpage>6</lpage>
          <issue>4</issue>
          <volume>86</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Amato</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Moffa</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Werner</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Ramires</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>17. Monin JL, Lancellotti    P, Monchi M, Lim P, Weiss E, Pierard L, et al. Risk score for predicting outcome    in patients with asymptomatic aortic stenosis. Circulation. 2009; 120 (1): 69-75.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Risk score for predicting outcome in patients with asymptomatic aortic stenosis</article-title>
          <source>Circulation</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>69</fpage>
          <lpage>75</lpage>
          <issue>1</issue>
          <volume>120</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Monin</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Lancellotti</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Monchi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pierard</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>18. Otto CM, Burwash    IG, Legget ME, Munt BI, Fujioka M, Healy NL, et al. Prospective study of asymptomatic    valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors    of outcome. Circulation. 1997; 95 (9): 2262-70.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prospective study of asymptomatic valvular aortic stenosis: Clinical, echocardiographic, and exercise predictors of outcome</article-title>
          <source>Circulation</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>2262</fpage>
          <lpage>70</lpage>
          <issue>9</issue>
          <volume>95</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Otto</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Burwash</surname>
              <given-names>IG</given-names>
            </name>
            <name>
              <surname>Legget</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Munt</surname>
              <given-names>BI</given-names>
            </name>
            <name>
              <surname>Fujioka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Healy</surname>
              <given-names>NL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>19. Pellikka PA,    Nishimura RA, Bailey KR, Tajik AJ. The natural history of adults with asymptomatic,    hemodynamically significant aortic stenosis. J Am Coll Cardiol. 1990; 15 (5):    1012-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The natural history of adults with asymptomatic, hemodynamically significant aortic stenosis</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>1012</fpage>
          <lpage>7</lpage>
          <issue>5</issue>
          <volume>15</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pellikka</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Nishimura</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Tajik</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>20. Pellikka PA,    Sarano ME, Nishimura RA, Malouf JF, Bailey KR, Scott CG, et al. Outcome of 622    adults with asymptomatic, hemodynamically significant aortic stenosis during    prolonged follow-up. Circulation. 2005; 111 (24): 3290-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>3290</fpage>
          <lpage>5</lpage>
          <issue>24</issue>
          <volume>111</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pellikka</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Sarano</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Nishimura</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Malouf</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>CG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>21. Rosenhek R,    Binder T, Porenta G, Lang I, Christ G, Schemper M, et al. Predictors of outcome    in severe, asymptomatic aortic stenosis. N Engl J Med. 2000; 343 (9): 611-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Predictors of outcome in severe, asymptomatic aortic stenosis</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>611</fpage>
          <lpage>7</lpage>
          <issue>9</issue>
          <volume>343</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rosenhek</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Binder</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Porenta</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lang</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Christ</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schemper</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>22. Bergler-Klein    J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel H, et al. Natriuretic    peptides predict symptom-free survival and postoperative outcome in severe aortic    stenosis. Circulation. 2004; 109 (19): 2302-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis</article-title>
          <source>Circulation</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>2302</fpage>
          <lpage>8</lpage>
          <issue>19</issue>
          <volume>109</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bergler-Klein</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Klaar</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Heger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rosenhek</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mundigler</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gabriel</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>23. Coglianese    EE, Davidoff R. Predicting outcome in patients with asymptomatic aortic stenosis.    Circulation. 2009; 120 (1): 9-11.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Predicting outcome in patients with asymptomatic aortic stenosis</article-title>
          <source>Circulation</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>9</fpage>
          <lpage>11</lpage>
          <issue>1</issue>
          <volume>120</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Coglianese</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Davidoff</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>24. Amato MC, Moffa    PJ. Prognosis of asymptomatic aortic valve stenosis evaluated with exercise    test. Arq Bras Cardiol. 1998; 70 (4): 251-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognosis of asymptomatic aortic valve stenosis evaluated with exercise test</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>251</fpage>
          <lpage>5</lpage>
          <issue>4</issue>
          <volume>70</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Amato</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Moffa</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>25. Pierri H, Nussbacher    A, D&#233;court LV, Medeiros C, Cattani A, Serro-Azul JB, et al. Clinical    predictors of prognosis in severe aortic stenosis in unoperated patients &gt;    or = 75 years of age. Am J Cardiol. 2000; 86 (7): 801-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical predictors of prognosis in severe aortic stenosis in unoperated patients &gt; or = 75 years of age</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>801</fpage>
          <lpage>4</lpage>
          <issue>7</issue>
          <volume>86</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pierri</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nussbacher</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>D&#233;court</surname>
              <given-names>LV</given-names>
            </name>
            <name>
              <surname>Medeiros</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cattani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Serro-Azul</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>26. Pierri H, D&#233;court    LV, Wajngarten M, Gebara O, Serro-Azul JB, Nussbacher A, et al. Perfil cl&#237;nico    de idosos portadores de estenose a&#243;rtica severa. Arq Bras Cardiol. 1997;    68 (6): 415-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Perfil cl&#237;nico de idosos portadores de estenose a&#243;rtica severa</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>415</fpage>
          <lpage>20</lpage>
          <issue>6</issue>
          <volume>68</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pierri</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>D&#233;court</surname>
              <given-names>LV</given-names>
            </name>
            <name>
              <surname>Wajngarten</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gebara</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Serro-Azul</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Nussbacher</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>27. Lancellotti    P, Lebois F, Simon M, Tombeux C, Chauvel C, Pierard LA. Prognostic importance    of quantitative exercise Doppler echocardiography in asymptomatic valvular aortic    stenosis. Circulation. 2005; 112 (9 Suppl): I377-I382.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic importance of quantitative exercise Doppler echocardiography in asymptomatic valvular aortic stenosis</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>I377</fpage>
          <lpage>I382</lpage>
          <volume>112</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lancellotti</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lebois</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tombeux</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Chauvel</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pierard</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>28. Lung B, Baron    G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, et al. A prospective    survey of patients with valvular heart disease in Europe: The Euro Heart Survey    on Valvular Heart Disease. Eur Heart J. 2003; 24 (13): 1231-43.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1231</fpage>
          <lpage>43</lpage>
          <issue>13</issue>
          <volume>24</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lung</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Baron</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Butchart</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Delahaye</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gohlke-Barwolf</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Levang</surname>
              <given-names>OW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>29. Rafique AM,    Biner S, Ray I, Forrester JS, Tolstrup K, Siegel RJ. Meta-analysis of prognostic    value of stress testing in patients with asymptomatic severe aortic stenosis.    Am J Cardiol. 2009;104 (7): 972-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Meta-analysis of prognostic value of stress testing in patients with asymptomatic severe aortic stenosis</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>972</fpage>
          <lpage>7</lpage>
          <issue>7</issue>
          <volume>104</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rafique</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Biner</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ray</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Forrester</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Tolstrup</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Siegel</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>30. Dal-Bianco    JP, Sengupta PP, Khandheria BK. Role of echocardiography in the diagnosis and    management of asymptomatic severe aortic stenosis. Expert Rev Cardiovasc Ther.    2008; 6 (2): 223-33.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Role of echocardiography in the diagnosis and management of asymptomatic severe aortic stenosis</article-title>
          <source>Expert Rev Cardiovasc Ther</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>223</fpage>
          <lpage>33</lpage>
          <issue>2</issue>
          <volume>6</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dal-Bianco</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Sengupta</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Khandheria</surname>
              <given-names>BK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>31. Dal-Bianco    JP, Khandheria BK, Mookadam F, Gentile F, Sengupta PP. Management of asymptomatic    severe aortic stenosis. J Am Coll Cardiol. 2008; 52 (16): 1279-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Management of asymptomatic severe aortic stenosis</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1279</fpage>
          <lpage>92</lpage>
          <issue>16</issue>
          <volume>52</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dal-Bianco</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Khandheria</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Mookadam</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gentile</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sengupta</surname>
              <given-names>PP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>32. Carabello BA,    Paulus WJ. Aortic stenosis. Lancet. 2009; 373 (9667): 956-66.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Aortic stenosis</article-title>
          <source>Lancet</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>956</fpage>
          <lpage>66</lpage>
          <issue>9667</issue>
          <volume>373</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Carabello</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Paulus</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>33. Lung B. Management    of the elderly patient with aortic stenosis. Heart. 2008; 94 (4): 519-24.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Management of the elderly patient with aortic stenosis</article-title>
          <source>Heart</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>519</fpage>
          <lpage>24</lpage>
          <issue>4</issue>
          <volume>94</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lung</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Severe aortic stenosis in asymptomatic patients: the dilemma of clinical versus surgical treatment</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>Aortic valve stenosis has become increasingly prevalent, in agreement with the aging of the population. Thus, it has become increasingly common to treat asymptomatic patients with severe aortic stenosis. Although the patients with asymptomatic aortic stenosis belong to the same group, they are heterogeneous from a clinical, laboratory and echocardiographic point of view. The treatment of these patients raises the dilemma of the clinical versus the surgical treatment: should we submit the patient to the risks of surgery or keep the patient under clinical observation, running the risk of irreversible myocardial damage or even sudden death? Under this perspective and based on the current literature, this study supplies tools that help to stratify the patients. The valvular area, degree of calcification, transvalvular aortic flow velocity, left ventricular hypertrophy and stress test alterations are the factors that place asymptomatic individuals with severe aortic stenosis in a group called very-high risk, in which the surgical approach starts to be considered.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Aortic valve stenosis</kwd>
        <kwd>ventricular dysfunction, left</kwd>
        <kwd>heart valve prosthesis implantation</kwd>
        <kwd>symptoms</kwd>
        <kwd>clinical</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>REVIEW ARTICLE</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Severe aortic stenosis in asymptomatic patients: the dilemma of clinical <italic>versus</italic> surgical treatment</bold>
          </label>
          <p>
            <bold>Marcelo Katz; Fl&#225;vio Tarasoutchi; Max Grinberg</bold>
          </p>
        </fn>
      </p>
      <p>Instituto do Cora&#231;&#227;o do Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo - S&#227;o Paulo, SP - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p>Aortic valve stenosis has become increasingly prevalent, in agreement with the aging of the population. Thus, it has become increasingly common to treat asymptomatic patients with severe aortic stenosis. Although the patients with asymptomatic aortic stenosis belong to the same group, they are heterogeneous from a clinical, laboratory and echocardiographic point of view. The treatment of these patients raises the dilemma of the clinical <italic>versus</italic> the surgical treatment: should we submit the patient to the risks of surgery or keep the patient under clinical observation, running the risk of irreversible myocardial damage or even sudden death? Under this perspective and based on the current literature, this study supplies tools that help to stratify the patients. The valvular area, degree of calcification, transvalvular aortic flow velocity, left ventricular hypertrophy and stress test alterations are the factors that place asymptomatic individuals with severe aortic stenosis in a group called very-high risk, in which the surgical approach starts to be considered.</p>
      <p><bold>Key words:</bold> Aortic valve stenosis; ventricular dysfunction, left/surgery; heart valve prosthesis implantation; symptoms, clinical.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>The prevalence of aortic stenosis (AoS) is growing, particularly that of degenerative etiology, mostly related to the aging of the population. The aging of the population is a worldwide phenomenon and it also occurs in Brazil. According to the estimates of the Brazilian Institute of Geography and Statistics (IBGE), by the year 2050, Brazilian individuals older than 75 years will represent 10% of the total population<sup>1</sup>. According to Lindroos et al<sup>2</sup>, in an echocardiographic study of AoS prevalence, approximately 3% of the population older than 75 years presents severe AoS of degenerative etiology<sup>2</sup>.</p>
      <p>The epidemiological importance of AoS can be estimated by projecting the Brazilian population scenario for the year 2050. The country will have 260,000,000 inhabitants and of these, approximately 10%, or 26,000,000, will be older than 75 years<sup>1</sup>.</p>
      <p>Considering the echocardiographic study by Lindroos, there will be 800,000 individuals older than 75 years with severe degenerative aortic stenosis. Adding these patients to those presenting AoS from the other age ranges and of different etiologies, this valvular disease can be considered a public health problem, further increasing the interest of its study.</p>
      <p>In addition to the epidemiological aspect, another question raised regarding the AoS is the approach in case of asymptomatic patients with severe AoS. It is understood that the asymptomatic patient is the one who does not present the classic symptoms of AoS: dyspnea, angina and syncope, regardless of the age range and/or etiology. The asymptomatic patient with severe AoS has been the object of much debate between clinicians and cardiologists in recent years. According to the previous paradigm, based on the observations made during the 1960s and 70s, the asymptomatic patients with severe AoS can be followed clinically, as long as they do not present systolic ventricular dysfunction, as the survival curve in this group is similar to that of the general population<sup>3</sup>.</p>
      <p>However, the concept of "benignity" of the severe asymptomatic AoS has been contested in the last years, supported by two premises:</p>
      <disp-quote>
        <p>1. Asymptomatic patients are not always really symptom-free, as they very often progressively try to limit their activities, thus masking the symptoms (mainly elderly patients); they are actually "pseudo-asymptomatic" patients and therefore, present a worse prognosis.</p>
        <p>2. The asymptomatic patients with severe AoS are not identical, i.e., even though they do not have symptoms and do not present left ventricular dysfunction, there are other variables that can increase or decrease the risk of these patients, making them, although part of the same group, a heterogeneous set of patients.</p>
      </disp-quote>
      <p>The objective of the present study, therefore, is to discuss, considering the current evidence, the best approach for the asymptomatic patient with severe AoS, by supplying tools that can help the decision-making of keeping the patient under observation or submitting him/her to the surgical treatment.</p>
      <p>
        <bold>Aortic stenosis: relevant aspects</bold>
      </p>
      <p>AoS is a valvular disease that affects the aortic valve and which is characterized by obstruction to the passage of blood flow from the left ventricular outflow tract to the aorta. Its main etiologies are rheumatic disease, degenerative disease, also called atherosclerotic etiology and congenital etiology<sup>4</sup>.</p>
      <p>Whatever the cause of the AoS, the final pathway is the calcification process and the progressive decrease in size of the valve orifice. During the AoS evolution, this progressive decrease in the valvular area determines left ventricular (LV) hypertrophy (LVH), initially with maintenance of systolic function. The LVH allows the patient to remain asymptomatic for a variable period of time. In time, there is an imbalance between the muscle, interstitial and vascular compartments, resulting in ischemia and myocardial damage. Progressive ventricular dysfunction occurs, initially of the diastolic type; in the final phase, systolic ventricular dysfunction is observed.</p>
      <p>Throughout the natural history of AoS, the onset of symptoms (dyspnea, angina and stress-induced syncope) is a marker of severity, with drastic implications on the survival curve of these patients<sup>3,5</sup>.</p>
      <p>The diagnosis of AoS is based on anamnesis, physical examination and complementary assessment. The anamnesis must be thorough, aiming at establishing the patient's actual functional capacity and identifying the presence of symptoms related to the aortic stenosis. It is very common for patients to limit their activities after symptom onset<sup>6</sup>.</p>
      <p>At the complementary assessment, the role of the Doppler echocardiography (ECHO) procedure is a crucial one<sup>7,8</sup>. The ECHO allows the diagnostic confirmation and the stratification of the severity of the AoS, which can be mild, moderate or severe.</p>
      <p>According to the American Heart Association<italic><sup>7</sup>,</italic> the severe AoS can be defined as that which presents a valvular area &lt; 1.0 cm<sup>2</sup>, mean aortic transvalvular gradient <underline>&gt;</underline> 40 mmHg, and/or peak systolic aortic jet velocity &gt; 4 m/s. A sub-classification of AoS as very severe AoS has been suggested<sup>9,10</sup>: it would be the one in which the aortic valve area is <underline>&lt;</underline> 0.7 cm<sup>2</sup> and/or indexed valve area is <underline>&lt;</underline> 0.4 cm<sup>2</sup>/m<sup>2</sup>.</p>
      <p>The definitive treatment of severe AoS, when indicated, is the surgical approach and the standard treatment, to date, consists in replacing the aortic valve with a prosthesis, which can be either biological or metallic.</p>
      <p>The main indications for the surgical treatment are<sup>7,8</sup>:</p>
      <disp-quote>
        <p>&#149; Severe AoS in symptomatic patients (dyspnea, angina and syncope)</p>
        <p>&#149; Severe AoS in patients that will be submitted to myocardial revascularization</p>
        <p>&#149; Severe AoS in patients that will be submitted to surgeries in the aorta or other valves</p>
        <p>&#149; Severe AoS in patients with ventricular systolic dysfunction</p>
      </disp-quote>
      <p>More recently, the technique of percutaneous aortic valve implantation<sup>11,12</sup> has been used. This procedure is carried out through the femoral vein and the biological aortic prosthesis is anchored on a wired structure that resembles a "large stent"; it is performed in centers that have experience with this procedure and it has not yet substituted the conventional surgical procedure, being reserved for selected cases with high surgical risk.</p>
      <p>
        <bold>Severe aortic stenosis in asymptomatic patients: the great dilemma</bold>
      </p>
      <p>The approach of patients with severe AoS initially allocates them in three groups:</p>
      <disp-quote>
        <p>&#149; Symptomatic patients with severe AoS and/or LV systolic dysfunction. These patients have formal indication for surgical treatment and, as long as there are no factors/comorbidities that contraindicate surgery, the latter must be considered the treatment of choice.</p>
        <p>&#149; Symptomatic patients with severe AoS and/or LV systolic dysfunction, but with comorbidities that contraindicate the surgical treatment, or patients that refuse to be submitted to the surgical procedure. In these cases, the treatment is palliative, although there is a future perspective of the alternative possibility of treatment through the percutaneous aortic valve implantation<sup>11,12</sup>.</p>
        <p>&#149; Finally, the third group, consisting of asymptomatic patients with severe AoS, with preserved ventricular function, the main object of this study. As mentioned before, although they belong to the same group, they comprise a heterogeneous set of patients. Therefore, the medical conduct must be individualized.</p>
      </disp-quote>
      <p>The therapeutic decision regarding the asymptomatic patient with severe AoS raises the dilemma: to keep the patient under clinical observation or submit the patient to a prophylactic surgery.</p>
      <p>The strategy to submit all asymptomatic patients with severe AoS to a prophylactic surgery is not a viable one. Considering that the "prophylactic surgery" were the routine approach, we would be exposing 100% of the asymptomatic patients with severe AoS to a 3% to 4% risk related to the surgical procedure, added to a 1% risk a year related to the presence of valvular prosthesis, benefiting approximately 1% of this population who would present the risk of sudden death per year<sup>5,13-15</sup>.</p>
      <p>On the other hand, to keep all patients from this group under clinical observation can be hazardous. In fact, more recent observational studies related to the natural history of severe AoS in asymptomatic patients have shown that this group is not so "benign" as believed in earlier decades<sup>16-21</sup>.</p>
      <p>In 1997, Otto et al<sup>18</sup> presented a study of 123 asymptomatic patients with severe AoS that were followed prospectively for 2.5 &#177; 1.4 years. In this study, the probability of symptom-free survival for asymptomatic patients was 93% in the first year, 62% in the third year and 26% in the fifth year. The multivariate analysis showed that the aortic jet velocity, the increase in the aortic jet velocity and the change in the functional status were independent predictors of death or need for surgery. For the patient, the probability of remaining alive, without the need for surgery at 2 years of follow-up was only 21% for those presenting aortic jet velocity &gt; 4 m/s at the study enrollment.</p>
      <p>In 2000, Rosenhek et al<sup>21</sup> published the results of a prospective study in which 126 asymptomatic patients with severe AoS were followed for 22 &#177; 18 months. At the end of the follow-up period, the probability of survival calculated for the asymptomatic patients was 93% in the first year, 91% in the second year and 87% in the fourth year. The multivariate analysis showed that the degree of aortic valve calcification was an independent predictor of combined events that included the development of symptoms and/or death. The probability of symptom-free survival for the asymptomatic patients that presented moderate or intense aortic valve calcification was 60% in the first year, 47% in the second year and only 20% in the fourth year.</p>
      <p>In 2001, Amato et al<sup>16</sup> reported the results of a prospective study that followed 66 asymptomatic patients with severe AoS. All patients were submitted to an ergometric test on treadmill, with the objective of stratifying them. There were four cases of sudden death during the follow-up and in these cases, the ergometric test had been positive and the aortic valve area was <underline>&lt;</underline> 0.6 cm<sup>2</sup>.</p>
      <p>In 2004, Bergler-Klein et al<sup>22</sup> studied the BNP and NT-proBNP as prognostic markers in patients with aortic stenosis. The focus was the analysis of symptom-free survival in asymptomatic patients. The BNP value &lt; 130 pg/ml and NT-proBNP value &lt; 80 pmol/l (678 pg/ml) were predictors of symptom-free survival for a period of six to nine months<sup>22</sup>.</p>
      <p>In 2005, the Pellikka et al<sup>20</sup> presented the results of a large study of 622 asymptomatic patients with severe AoS that were followed prospectively for 5 years. In this study, the probability of remaining symptom-free for patients not submitted to the surgical treatment was only 33% in 5 years, whereas the probability of survival without surgery was 25% in 5 years. The risk of sudden death, not preceded by symptoms, was approximately 1% a year. In this study, after 2 years of follow-up, the asymptomatic patient started to present a worse prognosis than that of the general population, even in the absence of symptoms. Age, chronic renal failure and aortic jet velocity were predictors of mortality<sup>20</sup>.</p>
      <p>More recently, Dr. Jean-Luc Monin&#180;s group et al<sup>17</sup> carried out a study of 107 asymptomatic patients with severe AoS<sup>17</sup>. The objective was to develop a risk score that could be applied and that would be able to predict the chance of these patients to present adverse events over time. The patients were followed for 24 months and death or need for surgical procedure was considered adverse events. The independent predictors of adverse events found in this study were used to construct the score, which was then applied to a second population of 107 asymptomatic patients with severe AoS, with the objective of validating the score. The outcome predictor variables were female sex, peak systolic aortic jet velocity and initial BNP value. A formula was constructed to calculate the score:</p>
      <p>
        <graphic xlink:href="1678-4170-abc-95-04-0541-00019-e01-en.jpg"/></p>
      <p>The values obtained for the score were grouped in quartiles: Q1 12.9; Q2 14.6; Q3 16.2 and Q4 19.7. The probability of event-free survival in 20 months was 80% among patients at the first quartile and only 7% among patients from the last quartile. Although the results of the study are significant, the systematic use of the risk score, proposed by Dr. Monin's group<sup>17</sup>, still needs to be validated, in order to become of routine use<sup>23</sup>.</p>
      <p>If, on the one hand, the prospective studies that assessed asymptomatic patients with severe AoS have shown that the risk of sudden death in these patients is around 1% a year, on the other hand they have also shown that the group is indeed heterogeneous and that clinical, laboratory and echocardiographic parameters determine a higher or lower risk for these patients.</p>
      <p>In addition to sudden death, the asymptomatic patients also present the risk of irreversible myocardial damage in cases when the surgery is postponed<sup>23</sup>. These risks must be taken into account when choosing between the conservative and the surgical strategies.</p>
      <p>Therefore, what has been sought is a more refined stratification of this group of patients, with the objective of identifying, among asymptomatic patients with severe AoS, those at higher risk who, consequently, would benefit from the surgery. That objective is exactly to prevent sudden death and/or irreversible myocardial damage. In this sense and based on more recent guidelines and observational studies, the main risk factors would be<sup>7,8,10</sup>:</p>
      <disp-quote>
        <p>&#149; Very severe AoS (aortic valve area <underline>&lt;</underline> 0.7 cm<sup>2</sup> or indexed valve area <underline>&lt;</underline> 0.4 cm<sup>2</sup>/m<sup>2</sup></p>
        <p>&#149; Accelerated increase in the severity of the AoS (defined as increase in the aortic jet velocity &gt; 0.30 m/s a year)</p>
        <p>&#149; Aortic valve calcification</p>
        <p>&#149; Presence of documented ischemia / coronary artery disease</p>
        <p>&#149; Ventricular systolic dysfunction (when present indicates surgery)</p>
        <p>&#149; LV dilation with systolic function impairment (afterload mismatch)</p>
        <p>&#149; Marked or rapidly progressive LV hypertrophy (12 to 14 mm in women and 14 to 16 mm in men)</p>
        <p>&#149; Age (&gt; 60 years)</p>
        <p>&#149; Other non-cardiac comorbidities</p>
      </disp-quote>
      <p>
        <bold>The answer to the dilemma: individualized management</bold>
      </p>
      <p>As shown before, although asymptomatic patients with severe AoS belong to the same group of patients, they are actually a heterogeneous set of patients from a clinical, laboratory and echocardiographic point of view. As a consequence, the prognosis also becomes dependent on these particularities and, therefore, the conduct for these patients must be individualized. At one extremity, for the low-risk patients, the conduct is a conservative, expectant one. At the other extremity, for the high-risk patients, the conduct is the surgical one, with aortic valve replacement.</p>
      <p>To individualize the risk in asymptomatic patients is also the suggestion of the main guidelines. According to the European consensus, asymptomatic patients with severe AoS that present preserved ventricular function, exuberant aortic valve calcification, rapid increase in the aortic jet velocity or stress test alterations would be candidates to surgery, as well as those that will be submitted to other concomitant cardiac surgery, such as associated myocardial revascularization<sup>8</sup>.</p>
      <p>The American consensus indicates surgery for patients who, albeit asymptomatic, present exuberant aortic valve calcification or rapid increase in the aortic jet velocity<sup>7</sup>. The national experience emphasizes the importance of the stress test in patient stratification<sup>16</sup>.</p>
      <p>Based on the exposed facts, we propose the following approach for the asymptomatic patient with severe AoS:</p>
      <p>
        <bold>1. Confirmation of severe AoS diagnosis</bold>
      </p>
      <p>The physical examination, complemented by the echocardiography, allows the confirmation of AoS and the assessment of its severity. According to the echocardiographic parameters, severe AoS can be defined as the one presenting mean aortic pressure gradient &gt; 40 mmHg, aortic valve area &lt; 1 cm<sup>2</sup> and/or peak systolic aortic jet velocity &gt; 4 m/s. It has been suggested that very severe AoS is the one in which the aortic valve area is &lt; 0.7 cm<sup>2</sup> or the indexed valve area is &lt; 0.4 cm<sup>2</sup>. When there are doubts about the severity of the AoS, a good alternative is to carry out a hemodynamic assessment, using manometry and detecting the transvalve aortic pressure gradient.</p>
      <p>
        <bold>2. Clarification of the actual functional status. Is the patient really asymptomatic or is the patient self-limited?</bold>
      </p>
      <p>The anamnesis of these patients must be detailed and thorough, focused on the patients' routine activities. It is very common for patients who walked without any problems to present now, at a more limited state, restricted to housework activities, and even so, declare that they feel fine, when they have actually ceased to perform at the previous level of effort.</p>
      <p>A good complementary alterative, in an attempt to clarify the question of functional status, would be to submit these patients to a functional assessment, such as the ergometric test<sup>24</sup>. The test can supply important data and select the so-called pseudo-asymptomatic patients. The test also helps in cases of isolated syncope (without angina or dyspnea). The isolated syncope, as the only clinical manifestation of AoS, is unusual <sup>25,26</sup>. In these cases, the presence of syncope during the test defines the symptom-exertion association, indicating the need for surgery. It is also worth mentioning that the stress test can also be associated to the echocardiography<sup>27</sup>. The stress-echocardiography is another method of functional stratification of these patients.</p>
      <p>Although the stress test is infrequently performed in clinical practice<sup>28</sup>, in a recent meta-analysis<sup>29</sup>, which analyzed the role of the ergometric test in the assessment of asymptomatic patients with severe AoS, the authors emphasized that the test is safe and effective to identify patients at high risk for adverse cardiac events and sudden death. The test can be used for risk stratification and to define the best moment to submit patients to the surgical procedure.</p>
      <p>The stress test is increasingly growing in recognition and whereas its recommendation is class IIb in the 2006 American guidelines for the management of patients with valvular heart disease<sup>7</sup>, the European Society of Cardiology in 2007 considers it beneficial and effective and included the test in the decision-making algorithm for asymptomatic patients with severe AoS<sup>8</sup>.</p>
      <p>
        <bold>3. Left ventricular function assessment</bold>
      </p>
      <p>The echocardiography allows the assessment of the systolic ventricular function<sup>30</sup>. In patients with severe AoS, even asymptomatic ones, if there is systolic ventricular dysfunction, the surgical treatment must be considered.</p>
      <p>
        <bold>4. Definition of clinical or surgical conducts for asymptomatic patients with severe AoS, with preserved ventricular function</bold>
      </p>
      <p>For these patients, the conduct must be individualized<sup>10,31</sup>. Some parameters can classify the patient as being very-high risk and among the aforementioned factors, the ones that define very high risk are:</p>
      <disp-quote>
        <p>&#149; Positive stress test (with evident symptoms or stress-induced hypotension)</p>
        <p>&#149; Aortic valve area <underline>&lt;</underline> 0.7 cm<sup>2</sup> or indexed valve area <underline>&lt;</underline> 0.4 cm<sup>2</sup>/m<sup>2</sup>. The body-surface indexed area is important due to the anthropometric differences observed in several patients.</p>
        <p>&#149; Rapidly progressive increase in aortic jet velocity, with an annual rate of increase &gt; 0.30 m/s a year.</p>
        <p>&#149; Moderate to intense aortic valve calcification, if associated with a rapid increase in aortic jet velocity.</p>
        <p>&#149; Marked ventricular hypertrophy, another marker of severity, especially when added to the reduced valvular area. The ventricular hypertrophy, on the one hand, allows the maintenance of cardiac output in the presence of the pressure overload caused by the AoS. On the other hand, it alters the diastolic function, decreases the coronary perfusion and is related to an increase in mortality<sup>32</sup>.</p>
      </disp-quote>
      <p>Based on the current literature, we suggest that asymptomatic patients with severe AoS who present very-high risk factors be considered candidates to surgical treatment. The surgical risk is relatively low, when compared to the risk of rapid development of symptoms and sudden death, specific for this group of very-high risk patients. Although there have been no randomized studies on the clinical <italic>versus</italic> surgical conduct in these patients, the strategy of not delaying the surgical treatment is being increasingly acknowledged, considering that the myocardial damage can be irreversible, the symptoms can develop rapidly without the patient's correct perception and the risk of sudden death can increase drastically.</p>
      <p>A special consideration must be given to the elderly population. When we analyze guidelines and consensuses, there is no reference to the age-limit that contraindicates the surgical treatment. In fact, what the studies reveal through series of cases is that the surgical treatment, even in the elderly patient, is better than the expectant conduct, when indicated<sup>33</sup>. Concerning the elderly patient, one must seek the very-high risk factors, but always taking the following equation into account: life expectancy x quality of life x risk of the surgical treatment, so that the best therapeutic decision can be achieved.</p>
      <p>
        <bold>Examples of clinical situations</bold>
      </p>
      <p>We will exemplify what has been discussed throughout this article through three clinical situations:</p>
      <p>
        <bold>Situation 1</bold>
      </p>
      <p>Fifty-three-year-old executive man, hypertensive and dyslipidemic, who was asymptomatic in his daily life, plays soccer with his friends twice a week. During a consultation with his cardiologist, a murmur suggestive of AoS is detected. The echocardiogram disclosed normal-sized cardiac chambers, septal and posterior wall thickness of 11 mm, normal biventricular function, calcified aortic valve with severe aortic stenosis, mean aortic pressure gradient of 45 mmHg, aortic jet velocity of 4.1 m/s and aortic valve area of 1 cm<sup>2</sup>. There are no alterations in the other valves. BNP level is 70 pg/ml. The cardiologist advises the patient to stop playing soccer and requests a stress test, of which results are normal and repeats the echocardiogram every six months, of which result is identical to the initial assessment. The indicated conduct is the expectant, conservative one. The patient is asked to return every six months or earlier in case of symptom onset.</p>
      <p>
        <bold>Situation 2</bold>
      </p>
      <p>Seventy-five-year-old retired man, asymptomatic in daily life, walks regularly. During a consultation with his cardiologist, a murmur suggestive of AoS is detected. The echocardiogram discloses normal-sized cardiac chambers, septal and posterior wall thickness of 12 mm, normal biventricular function, calcified aortic valve with severe AoS, mean aortic pressure gradient of 45 mmHg, aortic jet velocity of 4.2 m/s and aortic valve area of 0.9 cm<sup>2</sup>. There are no alterations in the other valves. BNP level is 100 pg/ml. The cardiologist requests a stress test, of which results are normal. The initial conduct is the expectant one and asks the patient to return in six months. At the return (6 months) the patient remains asymptomatic and a new echocardiogram disclosed septal and posterior wall thickness of 14 mm, normal biventricular function, calcified aortic valve with severe AoS, mean aortic pressure gradient of 58 mmHg, aortic jet velocity of 4.9 m/s and aortic valve area of 0.7 cm<sup>2</sup>. A rapid six-month evolution of the AoS is observed (increase in septal and wall thickness, decrease in aortic valve area, increase in aortic pressure gradient and jet velocity). The patient is classified as very-high risk due to the rapid evolution of the aortic stenosis and the surgical conduct is indicated.</p>
      <p>
        <bold>Situation 3</bold>
      </p>
      <p>Sixty-two-year-old woman, no diagnosed diseases, asymptomatic in daily life, retired. The daughter has observed that the mother seldom leaves the house and that her activities are being increasingly restricted to domestic activities. The cardiologist detects a murmur suggestive of AoS. The echocardiogram discloses normal-sized cardiac chambers, septal and posterior wall thickness of 13 mm, normal biventricular function, calcified aortic valve with severe AoS, mean aortic pressure gradient of 58 mmHg, aortic jet velocity of 4.8 m/s and aortic valve area of 0.8 cm<sup>2</sup>. There are no alterations in the other valves. BNP level is 200 pg/ml. The cardiologist indicates a stress test to evaluate the actual functional status of the patient: at the second minute of the test the patient presents hypotension with pre-syncope sensation and the test is interrupted, followed by the patient's total recovery. The cardiologist interprets the case as a very-high risk one, considers that the patient probably self-limited and indicates the aortic valve replacement surgery.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>The asymptomatic patients with severe AoS belong to a heterogeneous group of patients from the clinical, laboratory and echocardiographic point of view. Within this group, a number of patients classified as being very-high risk are noteworthy. The very-high risk criteria are: stress test alteration, aortic valve area <underline>&lt;</underline> 0.7 cm<sup>2</sup> or indexed valve area <underline>&lt;</underline> 0.4 cm<sup>2</sup>/m<sup>2</sup>, rapidly progressive transvalve aortic jet-velocity, moderate to intense aortic valve calcification, marked ventricular hypertrophy. For very-high risk patients, the surgical approach must be considered, in opposition to the conservative approach.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Art&#237;culo de Revisi&#243;n</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="es">Estenosis a&#243;rtica grave en pacientes asintom&#225;ticos: el dilema del tratamiento cl&#237;nico versus quir&#250;rgico</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>La estenosis valvular a&#243;rtica es cada vez m&#225;s prevalente concordante con el envejecimiento poblacional. Por consiguiente, se vuelve m&#225;s com&#250;n la atenci&#243;n de pacientes asintom&#225;ticos con estenosis a&#243;rtica grave. Aunque los pacientes con estenosis a&#243;rtica grave sin s&#237;ntomas hagan parte de un mismo grupo, son heterog&#233;neos bajo el punto de vista cl&#237;nico, de laboratorio y ecocardiogr&#225;fico. El abordaje de esos pacientes trae a cuento el dilema del tratamiento cl&#237;nico versus quir&#250;rgico: someter el paciente a los riesgos de la cirug&#237;a o mantenerlo en observaci&#243;n cl&#237;nica bajo el peligro de da&#241;o mioc&#225;rdico irreversible o aun de muerte s&#250;bita? Bajo esta perspectiva, bas&#225;ndose en la literatura actual, este art&#237;culo provee herramientas que auxilian en la estratificaci&#243;n de los pacientes. El &#225;rea valvar, grado de calcificaci&#243;n, velocidad de flujo transvalvar a&#243;rtico, hipertrofia ventricular izquierda y test de esfuerzo alterado son los factores que colocan a los portadores de estenosis a&#243;rtica grave asintom&#225;ticos en un grupo denominado de muy alto riesgo, en que la estrategia quir&#250;rgica pasa a ser considerada.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Estenosis de la valva a&#243;rtica</kwd>
        <kwd>implante de pr&#243;tesis de valva</kwd>
        <kwd>observaci&#243;n cl&#237;nica</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO DE REVISI&#211;N</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Estenosis a&#243;rtica grave en pacientes asintom&#225;ticos: el dilema del tratamiento cl&#237;nico <italic>versus</italic> quir&#250;rgico</bold>
          </label>
          <p>
            <bold>Marcelo Katz; Fl&#225;vio Tarasoutchi; Max Grinberg</bold>
          </p>
        </fn>
      </p>
      <p>Instituto do Cora&#231;&#227;o do Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo - S&#227;o Paulo, SP - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p>La estenosis valvular a&#243;rtica es cada vez m&#225;s prevalente concordante con el envejecimiento poblacional. Por consiguiente, se vuelve m&#225;s com&#250;n la atenci&#243;n de pacientes asintom&#225;ticos con estenosis a&#243;rtica grave. Aunque los pacientes con estenosis a&#243;rtica grave sin s&#237;ntomas hagan parte de un mismo grupo, son heterog&#233;neos bajo el punto de vista cl&#237;nico, de laboratorio y ecocardiogr&#225;fico. El abordaje de esos pacientes trae a cuento el dilema del tratamiento cl&#237;nico versus quir&#250;rgico: someter el paciente a los riesgos de la cirug&#237;a o mantenerlo en observaci&#243;n cl&#237;nica bajo el peligro de da&#241;o mioc&#225;rdico irreversible o aun de muerte s&#250;bita? Bajo esta perspectiva, bas&#225;ndose en la literatura actual, este art&#237;culo provee herramientas que auxilian en la estratificaci&#243;n de los pacientes. El &#225;rea valvar, grado de calcificaci&#243;n, velocidad de flujo transvalvar a&#243;rtico, hipertrofia ventricular izquierda y test de esfuerzo alterado son los factores que colocan a los portadores de estenosis a&#243;rtica grave asintom&#225;ticos en un grupo denominado de muy alto riesgo, en que la estrategia quir&#250;rgica pasa a ser considerada.</p>
      <p><bold>Palabras clave:</bold> Estenosis de la valva a&#243;rtica, disfunci&#243;n ventricular izquierda/cirug&#237;a, implante de pr&#243;tesis de valva, observaci&#243;n cl&#237;nica.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La prevalencia de estenosis a&#243;rtica (EAo) es creciente, particularmente la de etiolog&#237;a degenerativa, en gran parte relacionada al envejecimiento poblacional. El envejecimiento de la poblaci&#243;n es un fen&#243;meno mundial, y tambi&#233;n sucede en el Brasil. De acuerdo con estimativas del Instituto Brasileiro de Geografia y Estat&#237;stica (IBGE), en el a&#241;o de 2050, brasile&#241;os con edad superior a los 75 a&#241;os de edad representar&#225;n 10% del total poblacional<sup>1</sup>.</p>
      <p>De acuerdo con Lindroos et al<sup>2</sup>, en un estudio ecocardiogr&#225;fico de prevalencia de la EAo, aproximadamente 3% de la poblaci&#243;n encima de 75 a&#241;os de edad presenta EAo grave de etiolog&#237;a degenerativa<sup>2</sup>.</p>
      <p>La importancia epidemiol&#243;gica de la EAo puede ser estimada al proyectar el escenario poblacional brasile&#241;o para el a&#241;o 2050. El pa&#237;s tendr&#225; 260.000.000 de habitantes, siendo que de estos, aproximadamente 10%, o 26.000.000, ser&#225;n personas encima de 75 a&#241;os de edad<sup>1</sup>. Considerando el estudio ecocardiogr&#225;fico de Lindroos, tendremos 800.000 personas encima de 75 a&#241;os de edad con EAo grave degenerativa. Sumando estos pacientes a aquellos portadores de EAo de las dem&#225;s franjas et&#225;reas y etiolog&#237;as, podremos considerar esa enfermedad valvar como una cuesti&#243;n de salud p&#250;blica, aumentando aun m&#225;s el inter&#233;s en su estudio.</p>
      <p>Adem&#225;s del aspecto epidemiol&#243;gico, otra cuesti&#243;n que se levanta en relaci&#243;n a la EAo es el abordaje de los pacientes con EAo grave asintom&#225;ticos. Se entiende que el paciente asintom&#225;tico sea aquel que no presente los s&#237;ntomas cl&#225;sicos de la EAo: disnea, angina y s&#237;ncope, independiente de la franja et&#225;rea y/o etiolog&#237;a. El paciente con EAo grave, sin s&#237;ntomas, ha sido tema de mucho debate entre cl&#237;nicos y cardi&#243;logos en los &#250;ltimos a&#241;os. De acuerdo con el paradigma anterior, basado en observaciones de la d&#233;cada de 60 y 70, los portadores de EAo grave sin s&#237;ntomas podr&#237;an ser observados cl&#237;nicamente, desde que no presentasen disfunci&#243;n ventricular sist&#243;lica, una vez que la curva de sobrevida de ese grupo seria semejante a la de la poblaci&#243;n en general<sup>3</sup>.</p>
      <p>Entre tanto, el concepto de "benignidad" de la EAo grave sin s&#237;ntomas ha sido refutado en los &#250;ltimos a&#241;os, b&#225;sicamente apoyado en dos premisas:</p>
      <disp-quote>
        <p>1. No siempre el paciente asintom&#225;tico est&#225; realmente libre de s&#237;ntomas, muchas veces procuran limitar progresivamente sus actividades, enmascarando s&#237;ntomas (principalmente a&#241;osos); son en la realidad "seudo-asintom&#225;ticos", y, de esta forma, tiene peor pron&#243;stico.</p>
        <p>2. Los pacientes con estenosis a&#243;rtica grave asintom&#225;ticos no son id&#233;nticos, o sea, por m&#225;s que no tengan s&#237;ntomas y que no presenten disfunci&#243;n ventricular izquierda, existen otras variables que pueden aumentar o disminuir riesgo de estos pacientes, volvi&#233;ndolos, aunque parte de un mismo grupo, heterog&#233;neos.</p>
      </disp-quote>
      <p>El objetivo de este art&#237;culo, por lo tanto, es discutir, a la luz de las evidencias actuales, el mejor abordaje del paciente con estenosis a&#243;rtica grave asintom&#225;tico, proveyendo herramientas que auxilien en la decisi&#243;n de mantenerlo en observaci&#243;n cl&#237;nica o someterlo a tratamiento quir&#250;rgico.</p>
      <p>
        <bold>Estenosis a&#243;rtica: aspectos relevantes</bold>
      </p>
      <p>La EAo es una enfermedad valvar que acomete la valva a&#243;rtica, y que se caracteriza por la obstrucci&#243;n al pasaje del flujo sangu&#237;neo de la v&#237;a de salida del ventr&#237;culo izquierdo a la aorta. Tiene como principales etiolog&#237;as la enfermedad reum&#225;tica, degenerativa, tambi&#233;n denominada ateroscler&#243;tica, y cong&#233;nita<sup>4</sup>.</p>
      <p>Cualquiera que sea la causa de la EAo, la v&#237;a final es el proceso de calcificaci&#243;n, y reducci&#243;n progresiva del orificio valvar. En la evoluci&#243;n de la EAo, esta reducci&#243;n progresiva del &#225;rea valvar determina hipertrofia ventricular izquierda (HVI), inicialmente con manutenci&#243;n de la funci&#243;n sist&#243;lica. La HVI permite que el paciente permanezca asintom&#225;tico por un per&#237;odo variable de tiempo. Con el pasar del tiempo ocurre desequilibrio entre los compartimientos muscular, intersticial y vascular, resultando en isquemia y da&#241;o mioc&#225;rdico. Hay progresiva disfunci&#243;n ventricular, inicialmente diast&#243;lica; en la fase final se observa disfunci&#243;n ventricular sist&#243;lica.</p>
      <p>En la historia natural de la EAo, la aparici&#243;n de s&#237;ntomas (disnea, angina y s&#237;ncope inducida por el esfuerzo) es un marcador de gravedad, con implicaciones dr&#225;sticas en la curva de sobrevida de estos pacientes<sup>3,5</sup>.</p>
      <p>El diagn&#243;stico de la EAo se basa en la anamnesis, examen f&#237;sico, y evaluaci&#243;n complementaria. La anamnesis debe ser criteriosa procurando establecer la real capacidad funcional del paciente e identificar la presencia de s&#237;ntomas relacionados a la estenosis a&#243;rtica. Es muy com&#250;n que los pacientes limiten sus actividades con la aparici&#243;n de los s&#237;ntomas<sup>6</sup>.</p>
      <p>En la evaluaci&#243;n complementaria, se destaca el papel de la ecocardiograf&#237;a con Doppler (ECO)<sup>7,8</sup>. El ECO permite la confirmaci&#243;n diagn&#243;stica y la estratificaci&#243;n de gravedad de la EAo, que puede ser leve, moderada o grave. De acuerdo con la <italic>American Heart Association<sup>7</sup>,</italic> la EAo grave puede ser definida como aquella con &#225;rea valvar menor de 1,0 cm<sup>2</sup>, gradiente medio transvalvar a&#243;rtico mayor o igual a 40 mmHg, y/o velocidad de chorro transvalvar a&#243;rtico en el pico de la s&#237;stole mayor que 4 m/s. Una subclasificaci&#243;n de la EAo en EAo muy grave ha sido sugerida<sup>9,10</sup>. Ser&#237;a aquella con &#225;rea valvar a&#243;rtica menor o igual a 0,7 cm<sup>2</sup> y/o &#225;rea valvar indexada menor o igual a 0,4 cm<sup>2</sup>/m<sup>2</sup>.</p>
      <p>El tratamiento definitivo de la EAo grave, cuando es indicado, es quir&#250;rgico, siendo que el tratamiento est&#225;ndar, hasta el presente momento, es el reemplazo de la valva a&#243;rtica por una pr&#243;tesis, que puede ser biol&#243;gica o met&#225;lica. Las principales indicaciones para el tratamiento quir&#250;rgico son<sup>7,8</sup>:</p>
      <disp-quote>
        <p>&#149; EAo grave en pacientes sintom&#225;ticos (disnea, angina y s&#237;ncope)</p>
        <p>&#149; EAo grave en pacientes que ser&#225;n sometidos a la cirug&#237;a de revascularizaci&#243;n mioc&#225;rdica</p>
        <p>&#149; EAo grave en pacientes que ser&#225;n sometidos a la cirug&#237;a en aorta u otras v&#225;lvulas</p>
        <p>&#149; EAo grave en pacientes con disfunci&#243;n sist&#243;lica ventricular</p>
      </disp-quote>
      <p>M&#225;s recientemente, ha sido utilizada la t&#233;cnica de implante percut&#225;neo de la valva a&#243;rtica<sup>11,12</sup>. Se trata de procedimiento realizado por v&#237;a arterial femoral, con colocaci&#243;n de pr&#243;tesis biol&#243;gica a&#243;rtica sujetada en una estructura alambrada que recuerda un "gran stent", realizada en centros con experiencia en este procedimiento, siendo que aun no substituy&#243; al procedimiento quir&#250;rgico convencional; reservada a casos seleccionados en que hay alto riesgo quir&#250;rgico.</p>
      <p>
        <bold>Estenosis a&#243;rtica grave en pacientes asintom&#225;ticos: el gran dilema</bold>
      </p>
      <p>El abordaje de los pacientes con EAo grave distingue inicialmente 3 grupos:</p>
      <disp-quote>
        <p>&#149; Pacientes con EAo grave sintom&#225;ticos y/o con disfunci&#243;n sist&#243;lica del ventr&#237;culo izquierdo. Estos pacientes tienen indicaci&#243;n formal de tratamiento quir&#250;rgico, y desde que no haya factores/comorbilidades que contraindiquen la cirug&#237;a, esta debe ser considerada como tratamiento de elecci&#243;n.</p>
        <p>&#149; Pacientes con EAo grave sintom&#225;ticos y/o con disfunci&#243;n sist&#243;lica del ventr&#237;culo izquierdo, pero con comorbilidades que contraindiquen tratamiento quir&#250;rgico, o aun que rechacen cirug&#237;a. En estos casos el tratamiento ser&#225; paliativo, aunque haya perspectiva futura de posibilidad alternativa de tratamiento con implante percut&#225;neo de pr&#243;tesis valvar a&#243;rtica<sup>11,12</sup>.</p>
        <p>&#149; Finalmente, el tercer grupo, compuesto por pacientes con EAo grave, asintom&#225;ticos, con funci&#243;n ventricular preservada, objeto mayor de este art&#237;culo. Como destacamos, aunque hagan parte del mismo grupo, son heterog&#233;neos. La conducta, por lo tanto ser&#225; individualizada.</p>
      </disp-quote>
      <p>La decisi&#243;n terap&#233;utica para el paciente con EAo grave, asintom&#225;tico, trae el dilema: mantenerlo en observaci&#243;n cl&#237;nica, u operarlo profil&#225;cticamente.</p>
      <p>La estrategia de operar profil&#225;cticamente todos los pacientes con EAo grave asintom&#225;ticos no es viable. Imaginando que la "cirug&#237;a profil&#225;ctica" fuese la rutina, estar&#237;amos exponiendo 100% de los pacientes con EAo grave asintom&#225;ticos a un riesgo de 3% a 4% relacionado al procedimiento quir&#250;rgico, sumado a un riesgo de 1% al a&#241;o relacionado a la presencia de pr&#243;tesis valvar, beneficiando aproximadamente 1% de esta poblaci&#243;n que tendr&#237;a el riesgo de muerte s&#250;bita por a&#241;o<sup>5,13-15</sup>.</p>
      <p>Por otro lado, mantener todos los pacientes de ese grupo en observaci&#243;n cl&#237;nica puede no ser seguro. En realidad, estudios observacionales m&#225;s recientes relacionados a la historia natural de la EAo grave en asintom&#225;ticos, muestran que este grupo no es tan "benigno" como se imaginaba en d&#233;cadas anteriores<sup>16-21</sup>.</p>
      <p>En 1997, Otto et al<sup>18</sup> presentan un estudio en que 123 pacientes con EAo grave asintom&#225;ticos fueron controlados prospectivamente por 2,5 &#177; 1,4 a&#241;os. En ese estudio la probabilidad de sobrevida libre de s&#237;ntomas para los pacientes asintom&#225;ticos fue de 93% en el primer a&#241;o, 62% en el tercer a&#241;o y 26% en el quinto a&#241;o. A trav&#233;s de an&#225;lisis multivariado, la velocidad de chorro transvalvar a&#243;rtico, el aumento de la velocidad de chorro transvalvar a&#243;rtico y el cambio del status funcional fueron predictores independientes de &#243;bito o necesidad de cirug&#237;a. La probabilidad de que el paciente permanezca vivo, sin necesidad de cirug&#237;a a los 2 a&#241;os de seguimiento, fue de apenas 21% para los que presentaban en la inclusi&#243;n del estudio velocidad de chorro transvalvar a&#243;rtico mayor de 4 m/s.</p>
      <p>En 2000, Rosenhek et al<sup>21</sup> publican el resultado de un estudio prospectivo en que 126 pacientes portadores de EAo grave asintom&#225;ticos fueron seguidos por 22 &#177; 18 meses. Al final del control, la probabilidad de sobrevida calculada para los pacientes asintom&#225;ticos fue de 93% en el primer a&#241;o, 91% en el segundo a&#241;o y 87% en el cuarto a&#241;o. A trav&#233;s de an&#225;lisis multivariado, el grado de calcificaci&#243;n valvar fue predictor independiente de eventos combinados que incluyeron desarrollo de s&#237;ntomas y/o &#243;bito. La probabilidad de sobrevida libre de s&#237;ntomas para los pacientes asintom&#225;ticos que presentaban calcificaci&#243;n valvar a&#243;rtica moderada o intensa fue de 60% en el primer a&#241;o, 47% en el segundo a&#241;o y apenas 20% en el cuarto a&#241;o.</p>
      <p>En 2001, Amato et al<sup>16</sup> presentan el resultado de un estudio prospectivo que control&#243; 66 pacientes con EAo grave asintom&#225;ticos. Todos los pacientes fueron sometidos a test de esfuerzo en cinta, con el objetivo de estratificarlos. Hubo cuatro casos de muerte s&#250;bita durante el control, siendo que en estos, el test de esfuerzo hab&#237;a sido positivo y el &#225;rea valvar a&#243;rtica era menor o igual a 0,6 cm<sup>2</sup>.</p>
      <p>En 2004, Bergler-Klein et al<sup>22</sup> estudiaron el BNP y el NT-proBNP como marcadores pron&#243;sticos en pacientes con estenosis a&#243;rtica. El foco era en el an&#225;lisis de la sobrevida libre de s&#237;ntomas en asintom&#225;ticos. El valor de BNP menor que 130 pg/ml y de NT-proBNP menor que 80 pmol/L (678 pg/ml) fueron predictores de sobrevida libre de s&#237;ntomas por un per&#237;odo de 6 a 9 meses<sup>22</sup>.</p>
      <p>En 2005, el grupo de Pellikka et al<sup>20</sup> presenta el resultado de un gran estudio en que 622 pacientes asintom&#225;ticos con EAo grave fueron controlados prospectivamente por 5 a&#241;os. En ese estudio, la probabilidad de que pacientes no operados permanecieran libre de s&#237;ntomas fue de apenas 33% en 5 a&#241;os, mientras que la probabilidad de sobrevida sin cirug&#237;a fue de 25% en 5 a&#241;os. El riesgo de muerte s&#250;bita, no precedida por s&#237;ntomas, fue de aproximadamente 1% al a&#241;o. En ese trabajo, a partir de 2 a&#241;os de seguimiento, el paciente asintom&#225;tico pas&#243; a tener pron&#243;stico peor que la de la poblaci&#243;n en general, aun sin presentar s&#237;ntomas. Edad, insuficiencia renal cr&#243;nica y velocidad de chorro transvalvar a&#243;rtico fueron predictores de mortalidad<sup>20</sup>.</p>
      <p>M&#225;s recientemente, el grupo del Dr. Jean-Luc Monin et al<sup>17</sup> condujo un estudio que comprendi&#243; 107 pacientes con EAo grave asintom&#225;ticos. El objetivo era desarrollar un escore de riesgo que pudiese ser aplicado, y que fuese capaz de predecir la posibilidad de que estos pacientes presenten eventos adversos a lo largo del tiempo. Los pacientes fueron seguidos por 24 meses y &#243;bito o necesidad de cirug&#237;a fueron computados como evento adverso. Los predictores independientes de eventos adversos encontrados en este estudio fueron utilizados para la construcci&#243;n del escore, que enseguida fue aplicado en una segunda poblaci&#243;n de 107 pacientes con EAo grave, asintom&#225;ticos, con el prop&#243;sito de validar el escore. Las variables predictoras de desenlace fueron sexo femenino, velocidad de chorro transvalvar a&#243;rtico en el pico de la s&#237;stole, y el valor inicial del BNP. Una f&#243;rmula fue construida para calculo del escore:</p>
      <p>
        <graphic xlink:href="1678-4170-abc-95-04-0541-00019-e01-es.jpg"/></p>
      <p>Los valores obtenidos para el escore fueron agrupados en cuartiles: Q1 12,9; Q2 14,6; Q3 16,2 y Q4 19,7. La probabilidad de sobrevida libre de eventos en 20 meses fue de 80% en los pacientes del primer cuartil y apenas 7% entre los pacientes del &#250;ltimo cuartil. Aunque con resultados robustos, la aplicaci&#243;n sistem&#225;tica de escore de riesgo, propuesta por el grupo del Dr. Monin<sup>17</sup>, necesita de validaci&#243;n para volverse de rutina<sup>23</sup>.</p>
      <p>Si por un lado, los estudios prospectivos que evaluaron pacientes con EAo grave, asintom&#225;ticos, muestran que el riesgo de muerte s&#250;bita en esos pacientes es alrededor de 1% al a&#241;o, tambi&#233;n revelan que el grupo es realmente heterog&#233;neo, y que par&#225;metros cl&#237;nicos, de laboratorio y ecocardiogr&#225;ficos determinan mayor o menor riesgo para estos pacientes.</p>
      <p>El paciente asintom&#225;tico adem&#225;s de tener riesgo de muerte s&#250;bita, tiene tambi&#233;n riesgo de da&#241;o irreversible del miocardio en casos en que la cirug&#237;a es postergada<sup>23</sup>. Esos riesgos deben ser tenidos en cuenta para la elecci&#243;n de la estrategia conservadora o quir&#250;rgica.</p>
      <p>Lo que se ha buscado, por lo tanto, es la estratificaci&#243;n m&#225;s refinada de ese grupo de pacientes, con el objetivo de identificar, entre los pacientes con EAo grave asintom&#225;ticos, aquellos de mayor riesgo, y que, por lo tanto, se benefician de la cirug&#237;a. El objetivo es evitar justamente la muerte s&#250;bita y/o el da&#241;o irreversible del miocardio. Con este prop&#243;sito, y basado en directrices y estudios observacionales m&#225;s recientes, los principales factores de riesgo ser&#237;an<sup>7,8,10</sup>:</p>
      <disp-quote>
        <p>&#149; EAo muy grave (&#225;rea valvar <underline>&lt;</underline> 0,7 cm<sup>2</sup> o &#225;rea valvar indexada <underline>&lt;</underline> 0,4 cm<sup>2</sup>/m<sup>2</sup></p>
        <p>&#149; Incremento acelerado de gravedad de la EAo (definido como aumento en la velocidad de chorro transvalvar a&#243;rtico mayor que 0,30 m/s al a&#241;o)</p>
        <p>&#149; Calcificaci&#243;n valvar a&#243;rtica</p>
        <p>&#149; Presencia de isquemia documentada/ enfermedad arterial coronaria</p>
        <p>&#149; Disfunci&#243;n sist&#243;lica ventricular (cuando est&#225; presente indica cirug&#237;a)</p>
        <p>&#149; Dilataci&#243;n ventricular izquierda con p&#233;rdida de funci&#243;n sist&#243;lica ("<italic>afterload mismatch</italic>")</p>
        <p>&#149; Hipertrofia ventricular izquierda excesiva o r&#225;pidamente progresiva (12-14 mm en mujeres y 14-16 mm en hombres)</p>
        <p>&#149; Edad (encima de 60 a&#241;os de edad)</p>
        <p>&#149; Otras comorbilidades no card&#237;acas</p>
      </disp-quote>
      <p>
        <bold>La respuesta para el dilema: conducta individualizada</bold>
      </p>
      <p>Como fue expuesto, aunque pacientes con EAo grave asintom&#225;ticos hagan parte de un mismo grupo, en la realidad son heterog&#233;neos bajo el punto de vista cl&#237;nico, de laboratorio y ecocardiogr&#225;fico. Como consecuencia, tambi&#233;n el pron&#243;stico se vuelve dependiente de estas particularidades. Por lo tanto, la conducta para estos pacientes debe ser individualizada. En un extremo, para los pacientes de bajo riesgo, la conducta es conservadora, expectante. En el otro extremo, para los pacientes de alto riesgo, la conducta es quir&#250;rgica, con reemplazo valvar a&#243;rtica.</p>
      <p>Individualizar riesgo en pacientes asintom&#225;ticos tambi&#233;n es la sugesti&#243;n de las principales directrices. De acuerdo con el consenso europeo, pacientes con EAo grave asintom&#225;ticos, con funci&#243;n ventricular preservada, que presenten calcificaci&#243;n valvar exuberante, r&#225;pido aumento de la velocidad de chorro transvalvar a&#243;rtico, o aun test de esfuerzo alterado ser&#237;an candidatos a cirug&#237;a, as&#237; como aquellos que ser&#225;n sometidos a otra cirug&#237;a card&#237;aca concomitante, por ejemplo revascularizaci&#243;n mioc&#225;rdica asociada<sup>8</sup>. El consenso americano indica cirug&#237;a para los pacientes que a pesar de asintom&#225;ticos, presenten calcificaci&#243;n valvar exuberante o r&#225;pido aumento de la velocidad de chorro transvalvar a&#243;rtico<sup>7</sup>. La experiencia nacional destaca la importancia del test de esfuerzo en la estratificaci&#243;n de estos pacientes<sup>16</sup>.</p>
      <p>Basados en lo que fue exposto, proponemos el siguiente abordaje para el paciente asintom&#225;tico con EAo grave:</p>
      <p>
        <bold>1. Confirmaci&#243;n del diagn&#243;stico de EAo grave</bold>
      </p>
      <p>El examen f&#237;sico, complementado por la ecocardiograf&#237;a permite la confirmaci&#243;n de la EAo y la evaluaci&#243;n de su gravedad. De acuerdo con los par&#225;metros ecocardiogr&#225;ficos, EAo grave puede ser definida como aquella que presenta gradiente medio de presi&#243;n transvalvar a&#243;rtico mayor que 40 mmHg, &#225;rea valvar a&#243;rtica menor que 1 cm<sup>2</sup> y/o velocidad de chorro transvalvar a&#243;rtico en el pico de la s&#237;stole mayor que 4 m/s. Se sugiere que EAo muy grave sea aquella en que el &#225;rea valvar es menor que 0,7 cm<sup>2</sup> o el &#225;rea valvar indexada es menor que 0,4 cm<sup>2</sup>. Cuando haya dudas acerca de la gravedad de la EAo, una buena alternativa es la evaluaci&#243;n hemodin&#225;mica, con realizaci&#243;n de manometr&#237;a y detecci&#243;n de gradiente de presi&#243;n transvalvar a&#243;rtico.</p>
      <p>
        <bold>2. Elucidaci&#243;n del real status funcional. &#191;Ser&#225; que el paciente es realmente asintom&#225;tico o esta autolimitado?</bold>
      </p>
      <p>La anamnesis de estos pacientes debe ser detallada y exhaustiva, enfocada en las actividades cotidianas de los pacientes. Es muy com&#250;n que un paciente que caminaba sin problemas, ahora, m&#225;s limitado, se restrinja en las tareas dom&#233;sticas, y aun as&#237; dice que se siente bien, cuando en verdad dej&#243; de ejecutar el nivel de esfuerzo de otrora.</p>
      <p>Una buena alternativa complementaria, en la tentativa de elucidar la cuesti&#243;n del status funcional, seria someter esos pacientes a una evaluaci&#243;n funcional, como por ejemplo, el test ergom&#233;trico<sup>24</sup>. El test puede proveer datos importantes y seleccionar pacientes dichos seudoasintom&#225;ticos. El test tambi&#233;n auxilia en los casos de s&#237;ncope aislado (sin angina o disnea). El s&#237;ncope aislado, como &#250;nica manifestaci&#243;n cl&#237;nica de la EAo, es poco com&#250;n<sup>25,26</sup>. En esos casos, la presencia de s&#237;ncope durante el test define la asociaci&#243;n s&#237;ntoma-esfuerzo, indicando la cirug&#237;a. Dest&#225;quese, aun, que el test de esfuerzo puede inclusive ser asociado a la ecocardiograf&#237;a<sup>27</sup>. La ecocardiograf&#237;a de esfuerzo es otro m&#233;todo de estratificaci&#243;n funcional de estos pacientes.</p>
      <p>Aunque el test de esfuerzo sea poco realizado en la pr&#225;ctica cl&#237;nica<sup>28</sup>, en metan&#225;lisis reciente<sup>29</sup>, que analiz&#243; el papel del test ergom&#233;trico en la evaluaci&#243;n de pacientes con EAo grave asintom&#225;ticos, los autores destacan que el test es seguro y eficaz para identificar pacientes con alto riesgo para eventos card&#237;acos adversos y muerte s&#250;bita. El test puede ser utilizado para estratificaci&#243;n de riesgo y para definici&#243;n del mejor momento para operar a los pacientes.</p>
      <p>El test de esfuerzo gana cada vez m&#225;s espacio, y mientras su recomendaci&#243;n es clase IIb en el consenso americano de valvopat&#237;as<sup>7</sup> de 2006, la sociedad europea de cardiolog&#237;a en 2007 lo coloca como ben&#233;fico y efectivo, incluyendo el test en el algoritmo de toma de decisi&#243;n para los pacientes con EAo grave asintom&#225;ticos<sup>8</sup>.</p>
      <p>
        <bold>3. Evaluaci&#243;n de la funci&#243;n ventricular izquierda</bold>
      </p>
      <p>La ecocardiograf&#237;a permite la evaluaci&#243;n de la funci&#243;n ventricular sist&#243;lica<sup>30</sup>. En los pacientes con EAo grave, aun asintom&#225;ticos, se hay disfunci&#243;n ventricular sist&#243;lica, el tratamiento quir&#250;rgico debe ser considerado.</p>
      <p>
        <bold>4. Definici&#243;n de conducta cl&#237;nica o quir&#250;rgica para los pacientes con EAo grave, asintom&#225;ticos, con funci&#243;n ventricular preservada</bold>
      </p>
      <p>En estos pacientes, la conducta debe ser individualizada<sup>10,31</sup>. Algunos par&#225;metros pueden colocar el paciente en muy alto riesgo, y entre los factores presentados anteriormente, aquellos que definen muy alto riesgo son:</p>
      <disp-quote>
        <p>&#149; Test de esfuerzo positivo (con s&#237;ntomas evidentes o hipotensi&#243;n al esfuerzo).</p>
        <p>&#149; &#193;rea valvar a&#243;rtica menor o igual a 0,7 cm<sup>2</sup> o &#225;rea valvar indexada menor o igual a 0,4 cm<sup>2</sup>/m<sup>2</sup>. La indexaci&#243;n del &#225;rea por la superficie corporal es importante por las diferencias antropom&#233;tricas en los diversos pacientes.</p>
        <p>&#149; Velocidad de chorro transvalvar a&#243;rtico r&#225;pidamente progresiva, con tasa de aumento anual mayor que 0,30 m/s al a&#241;o.</p>
        <p>&#149; Calcificaci&#243;n valvar a&#243;rtica moderada a intensa si es asociada con r&#225;pido aumento de la velocidad de flujo transvalvar a&#243;rtico.</p>
        <p>&#149; Hipertrofia ventricular excesiva, otro marcador de gravedad, especialmente si es sumada al &#225;rea valvar reducida. La hipertrofia ventricular por un lado permite la manutenci&#243;n del d&#233;bito card&#237;aco frente a la sobrecarga pres&#243;rica impuesta por la EAo. Por otro lado, altera la funci&#243;n diast&#243;lica, disminuye perfusi&#243;n coronaria y est&#225; relacionada con aumento de mortalidad<sup>32</sup>.</p>
      </disp-quote>
      <p>Sugerimos, basados en la literatura actual, que pacientes asintom&#225;ticos con estenosis a&#243;rtica grave, que presenten los factores de muy alto riesgo sean candidatos al tratamiento quir&#250;rgico. El riesgo quir&#250;rgico es relativamente bajo comparado al riesgo de r&#225;pido desarrollo de s&#237;ntomas y muerte s&#250;bita espec&#237;fico para ese grupo de muy alto riesgo. Aunque aun no haya estudio randomizado que aborde conducta cl&#237;nica <italic>versus</italic> quir&#250;rgica en esos pacientes, es cada vez m&#225;s aceptada la estrategia de no retardar el tratamiento quir&#250;rgico, esto porque el da&#241;o miocardio puede ser irreversible, los s&#237;ntomas pueden desarrollarse r&#225;pidamente sin la correcta percepci&#243;n del paciente, y el riesgo de muerte s&#250;bita se eleva dr&#225;sticamente.</p>
      <p>Una consideraci&#243;n especial debe ser dada a la poblaci&#243;n de a&#241;osos. Cuando analizamos consensos y directrices, no hay referencia a la edad- l&#237;mite que contraindique el tratamiento quir&#250;rgico. En realidad, lo que los estudios revelan a trav&#233;s de series de casos, es que aun en el a&#241;oso, el tratamiento quir&#250;rgico, cuando es indicado, es mejor que la conducta expectante<sup>33</sup>. Trat&#225;ndose del paciente a&#241;oso, deberemos buscar los factores de muy alto riesgo, pero siempre teniendo en consideraci&#243;n la ecuaci&#243;n: expectativa de vida x calidad de vida x riesgo del tratamiento quir&#250;rgico, para que la mejor decisi&#243;n terap&#233;utica sea tomada.</p>
      <p>
        <bold>Ejemplos de situaciones cl&#237;nicas</bold>
      </p>
      <p>Ejemplificaremos lo que fue discutido en este art&#237;culo a trav&#233;s de tres situaciones cl&#237;nicas:</p>
      <p>
        <bold>Situaci&#243;n 1</bold>
      </p>
      <p>Hombre de 53 a&#241;os, ejecutivo, hipertenso y dislipid&#233;mico, asintom&#225;tico en el d&#237;a a d&#237;a, juega f&#250;tbol de campo con los amigos 2 veces por semana. En consulta con el cardi&#243;logo, detectado soplo sugestivo de EAo. Ecocardiograma revela: c&#225;maras card&#237;acas con dimensiones normales, espesor del septo y de la pared posterior de 11 mm, funci&#243;n biventricular normal, valva a&#243;rtica calcificada, con estenosis a&#243;rtica grave, gradiente medio de presi&#243;n transvalvar a&#243;rtico de 45 mmHg, velocidad de chorro transvalvar a&#243;rtico de 4,1 m/s, &#225;rea valvar a&#243;rtica de 1 cm<sup>2</sup>. Dem&#225;s valvas sin alteraciones. BNP de 70 pg/ml. El cardi&#243;logo orienta evitar el f&#250;tbol, indica un test de esfuerzo, que es normal, y repite el ecocardiograma en 6 meses, cuyo resultado es id&#233;ntico al examen inicial. La conducta indicada es expectante, conservadora. Indicado retornos semestrales o m&#225;s precoces si aparecen s&#237;ntomas.</p>
      <p>
        <bold>Situaci&#243;n 2</bold>
      </p>
      <p>Hombre de 75 a&#241;os, jubilado, asintom&#225;tico en el d&#237;a a d&#237;a, camina regularmente. En consulta con el cardi&#243;logo es detectado soplo sugestivo de EAo. El ecocardiograma revela: c&#225;maras card&#237;acas de dimensiones normales, espesor del septo y de la pared posterior de 12 mm, funci&#243;n biventricular normal, valva a&#243;rtica calcificada, con estenosis a&#243;rtica grave, gradiente medio de presi&#243;n transvalvar a&#243;rtico de 45 mmHg, velocidad de chorro transvalvar a&#243;rtico de 4,2 m/s, &#225;rea valvar a&#243;rtica de 0,9 cm<sup>2</sup>. Dem&#225;s valvas sin alteraciones. BNP de 100 pg/ml. El cardi&#243;logo indica un test de esfuerzo, que es normal. La conducta inicial es expectante, con retorno en 6 meses. En el retorno (6 meses) el paciente permanece asintom&#225;tico, y nuevo ecocardiograma revela espesor del septo y de la pared posterior de 14 mm, funci&#243;n biventricular normal, valva a&#243;rtica calcificada, con estenosis a&#243;rtica grave, gradiente medio de presi&#243;n transalvar a&#243;rtico de 58 mmHg, velocidad de chorro transvalvar a&#243;rtico de 4,9 m/s, &#225;rea valvar a&#243;rtica de 0,7 cm<sup>2</sup> . Se observa r&#225;pida evoluci&#243;n de la EAo en 6 meses (aumento de la espesor de septo y pared, disminuci&#243;n de &#225;rea valvar, aumento de gradiente y velocidad de chorro). El paciente es clasificado como de muy alto riesgo por la r&#225;pida evoluci&#243;n de la estenosis a&#243;rtica y conducta indicada es quir&#250;rgica.</p>
      <p>
        <bold>Situaci&#243;n 3</bold>
      </p>
      <p>Mujer de 62 a&#241;os, sin enfermedades diagnosticadas, asintom&#225;tica en el d&#237;a a d&#237;a, jubilada. La hija not&#243; que la madre hab&#237;a salido menos a la calle, y sus actividades son cada vez m&#225;s dom&#233;sticas. El cardi&#243;logo detect&#243; soplo sugestivo de EAo. Ecocardiograma revela: c&#225;maras card&#237;acas con dimensiones normales, espesor del septo y de la pared posterior de 13 mm, funci&#243;n biventricular normal, valva a&#243;rtica calcificada, con estenosis a&#243;rtica grave, gradiente medio de presi&#243;n transvalvar a&#243;rtico de 58 mmHg, velocidad de chorro transvalvar a&#243;rtico de 4,8 m/s y &#225;rea valvar de 0,8 cm<sup>2</sup>. Dem&#225;s valvas sin alteraciones. BNP de 200 pg/ml. El cardi&#243;logo indica un test de esfuerzo para evaluaci&#243;n del real status funcional de la paciente: en el segundo minuto del test la paciente presenta hipotensi&#243;n con sensaci&#243;n de pre s&#237;ncope, y el test es interrumpido, con recuperaci&#243;n total de la paciente. El cardi&#243;logo interpreta el caso como de muy alto riesgo, juzga que probablemente la paciente se auto limitaba, e indica cirug&#237;a de reemplazo valvar a&#243;rtica.</p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>Los pacientes con EAo grave asintom&#225;ticos hacen parte de un grupo heterog&#233;neo del punto de vista cl&#237;nico, de laboratorio y ecocardiogr&#225;fico. Se destaca dentro de este grupo, un grupo de pacientes clasificados como de muy alto riesgo. Los criterios de muy alto riesgo son: Test de esfuerzo alterado, &#225;rea valvar a&#243;rtica menor o igual a 0,7 cm<sup>2</sup> o &#225;rea valvar indexada menor o igual a 0,4 cm<sup>2</sup>/m<sup>2</sup>, velocidad de chorro transvalvar a&#243;rtico r&#225;pidamente progresiva, calcificaci&#243;n valvar a&#243;rtica moderada a intensa, hipertrofia ventricular excesiva. Para los pacientes de muy alto riesgo la estrategia quir&#250;rgica debe ser considerada frente a la conducta conservadora.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiamiento</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiamiento externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de post-grado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
